US20200179480A1 - Compositions and methods for treating precocious puberty - Google Patents
Compositions and methods for treating precocious puberty Download PDFInfo
- Publication number
- US20200179480A1 US20200179480A1 US16/793,391 US202016793391A US2020179480A1 US 20200179480 A1 US20200179480 A1 US 20200179480A1 US 202016793391 A US202016793391 A US 202016793391A US 2020179480 A1 US2020179480 A1 US 2020179480A1
- Authority
- US
- United States
- Prior art keywords
- histrelin
- implant
- patient
- month
- visit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 208000006155 precocious puberty Diseases 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title description 28
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 claims abstract description 133
- 108700020746 histrelin Proteins 0.000 claims abstract description 117
- 229960002193 histrelin Drugs 0.000 claims abstract description 116
- 208000015474 Central precocious puberty Diseases 0.000 claims abstract description 30
- 239000007943 implant Substances 0.000 claims description 139
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims description 31
- GNSFRPWPOGYVLO-UHFFFAOYSA-N 3-hydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCO GNSFRPWPOGYVLO-UHFFFAOYSA-N 0.000 claims description 29
- 238000009472 formulation Methods 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 20
- 238000002513 implantation Methods 0.000 claims description 18
- 229960003911 histrelin acetate Drugs 0.000 claims description 16
- 230000036470 plasma concentration Effects 0.000 claims description 15
- 238000013270 controlled release Methods 0.000 claims description 14
- OKKRPWIIYQTPQF-UHFFFAOYSA-N Trimethylolpropane trimethacrylate Chemical compound CC(=C)C(=O)OCC(CC)(COC(=O)C(C)=C)COC(=O)C(C)=C OKKRPWIIYQTPQF-UHFFFAOYSA-N 0.000 claims description 11
- 238000001727 in vivo Methods 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 9
- 229920001480 hydrophilic copolymer Polymers 0.000 claims description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- 235000021355 Stearic acid Nutrition 0.000 claims description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 5
- 239000008117 stearic acid Substances 0.000 claims description 5
- 238000007334 copolymerization reaction Methods 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 claims 6
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 abstract description 46
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract description 45
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 abstract description 37
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 abstract description 37
- 239000000463 material Substances 0.000 abstract description 28
- 239000000556 agonist Substances 0.000 abstract description 20
- 239000000017 hydrogel Substances 0.000 description 60
- 238000011282 treatment Methods 0.000 description 35
- 239000000178 monomer Substances 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 229920001577 copolymer Polymers 0.000 description 28
- 239000012528 membrane Substances 0.000 description 25
- 102000009151 Luteinizing Hormone Human genes 0.000 description 24
- 108010073521 Luteinizing Hormone Proteins 0.000 description 24
- 229940040129 luteinizing hormone Drugs 0.000 description 24
- 150000001875 compounds Chemical class 0.000 description 23
- 239000013543 active substance Substances 0.000 description 18
- 239000007788 liquid Substances 0.000 description 18
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 238000012377 drug delivery Methods 0.000 description 17
- 229960005309 estradiol Drugs 0.000 description 17
- 229930182833 estradiol Natural products 0.000 description 17
- 229920000642 polymer Polymers 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 238000003780 insertion Methods 0.000 description 16
- 230000037431 insertion Effects 0.000 description 16
- 238000009792 diffusion process Methods 0.000 description 15
- 238000011156 evaluation Methods 0.000 description 15
- 102000006771 Gonadotropins Human genes 0.000 description 14
- 108010086677 Gonadotropins Proteins 0.000 description 14
- 239000002622 gonadotropin Substances 0.000 description 14
- 238000006116 polymerization reaction Methods 0.000 description 11
- 230000001629 suppression Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 210000000988 bone and bone Anatomy 0.000 description 10
- -1 carboxylate salts Chemical class 0.000 description 10
- 108700012941 GNRH1 Proteins 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 229920001519 homopolymer Polymers 0.000 description 8
- 230000036571 hydration Effects 0.000 description 8
- 238000006703 hydration reaction Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 210000000481 breast Anatomy 0.000 description 7
- 239000003431 cross linking reagent Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 230000000887 hydrating effect Effects 0.000 description 7
- 231100000252 nontoxic Toxicity 0.000 description 7
- 230000003000 nontoxic effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- ZBVJFYPGLGEMIN-OYLNGHKZSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-( Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1.C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 ZBVJFYPGLGEMIN-OYLNGHKZSA-N 0.000 description 5
- 239000004971 Cross linker Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229920001477 hydrophilic polymer Polymers 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 208000023699 Familial male-limited precocious puberty Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 3
- BQZJOQXSCSZQPS-UHFFFAOYSA-N 2-methoxy-1,2-diphenylethanone Chemical group C=1C=CC=CC=1C(OC)C(=O)C1=CC=CC=C1 BQZJOQXSCSZQPS-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229940094892 gonadotropins Drugs 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 230000000379 polymerizing effect Effects 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 230000002294 pubertal effect Effects 0.000 description 3
- 210000003370 receptor cell Anatomy 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000011800 void material Substances 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- KUDUQBURMYMBIJ-UHFFFAOYSA-N 2-prop-2-enoyloxyethyl prop-2-enoate Chemical compound C=CC(=O)OCCOC(=O)C=C KUDUQBURMYMBIJ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 108010037003 Buserelin Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010069236 Goserelin Proteins 0.000 description 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 108010021717 Nafarelin Proteins 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 210000004198 anterior pituitary gland Anatomy 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 2
- NSGQRLUGQNBHLD-UHFFFAOYSA-N butan-2-yl butan-2-yloxycarbonyloxy carbonate Chemical compound CCC(C)OC(=O)OOC(=O)OC(C)CC NSGQRLUGQNBHLD-UHFFFAOYSA-N 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- ZQMIGQNCOMNODD-UHFFFAOYSA-N diacetyl peroxide Chemical compound CC(=O)OOC(C)=O ZQMIGQNCOMNODD-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 230000000423 heterosexual effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940127249 oral antibiotic Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000035938 sexual maturation Effects 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- WRXCBRHBHGNNQA-UHFFFAOYSA-N (2,4-dichlorobenzoyl) 2,4-dichlorobenzenecarboperoxoate Chemical compound ClC1=CC(Cl)=CC=C1C(=O)OOC(=O)C1=CC=C(Cl)C=C1Cl WRXCBRHBHGNNQA-UHFFFAOYSA-N 0.000 description 1
- NOBYOEQUFMGXBP-UHFFFAOYSA-N (4-tert-butylcyclohexyl) (4-tert-butylcyclohexyl)oxycarbonyloxy carbonate Chemical compound C1CC(C(C)(C)C)CCC1OC(=O)OOC(=O)OC1CCC(C(C)(C)C)CC1 NOBYOEQUFMGXBP-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- MKPHQUIFIPKXJL-UHFFFAOYSA-N 1,2-dihydroxypropyl 2-methylprop-2-enoate Chemical compound CC(O)C(O)OC(=O)C(C)=C MKPHQUIFIPKXJL-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical class CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- KWEBKUMFMORVPN-UHFFFAOYSA-N 1-ethenyl-3-methylazepan-2-one Chemical compound CC1CCCCN(C=C)C1=O KWEBKUMFMORVPN-UHFFFAOYSA-N 0.000 description 1
- SKZQCIFYKYXCTI-UHFFFAOYSA-N 1-ethenyl-4,6-dimethylazepan-2-one Chemical compound CC1CC(C)CC(=O)N(C=C)C1 SKZQCIFYKYXCTI-UHFFFAOYSA-N 0.000 description 1
- JWYVGKFDLWWQJX-UHFFFAOYSA-N 1-ethenylazepan-2-one Chemical class C=CN1CCCCCC1=O JWYVGKFDLWWQJX-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- QRIMLDXJAPZHJE-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(O)CO QRIMLDXJAPZHJE-UHFFFAOYSA-N 0.000 description 1
- OLQFXOWPTQTLDP-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOCCO OLQFXOWPTQTLDP-UHFFFAOYSA-N 0.000 description 1
- ZKLMKZINKNMVKA-UHFFFAOYSA-N 2-(2-hydroxypropoxy)propan-1-ol;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CC(O)COC(C)CO ZKLMKZINKNMVKA-UHFFFAOYSA-N 0.000 description 1
- JJBFVQSGPLGDNX-UHFFFAOYSA-N 2-(2-methylprop-2-enoyloxy)propyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OC(C)COC(=O)C(C)=C JJBFVQSGPLGDNX-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- VFZKVQVQOMDJEG-UHFFFAOYSA-N 2-prop-2-enoyloxypropyl prop-2-enoate Chemical compound C=CC(=O)OC(C)COC(=O)C=C VFZKVQVQOMDJEG-UHFFFAOYSA-N 0.000 description 1
- FRIBMENBGGCKPD-UHFFFAOYSA-N 3-(2,3-dimethoxyphenyl)prop-2-enal Chemical compound COC1=CC=CC(C=CC=O)=C1OC FRIBMENBGGCKPD-UHFFFAOYSA-N 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- 208000028060 Albright disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- OBBPNUOHIHIMFF-UHFFFAOYSA-N CCC(C)(C)C(=O)OCCCO Chemical compound CCC(C)(C)C(=O)OCCCO OBBPNUOHIHIMFF-UHFFFAOYSA-N 0.000 description 1
- CRUFITZJZGASJI-UHFFFAOYSA-N CCC(C)(C)C(=O)OCCO Chemical compound CCC(C)(C)C(=O)OCCO CRUFITZJZGASJI-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010049290 Feminisation acquired Diseases 0.000 description 1
- 208000034793 Feminization Diseases 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 201000001853 McCune-Albright syndrome Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010062282 Silver-Russell syndrome Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- 206010047486 Virilism Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 150000003926 acrylamides Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052936 alkali metal sulfate Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000005821 brain abnormality Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 208000015134 congenital hypothalamic hamartoma syndrome Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000001135 feminizing effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 150000004680 hydrogen peroxides Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000004185 hypothalamic-pituitary-gonadal axis Effects 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000794 masculinization Toxicity 0.000 description 1
- 229920002529 medical grade silicone Polymers 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- WFKDPJRCBCBQNT-UHFFFAOYSA-N n,2-dimethylprop-2-enamide Chemical compound CNC(=O)C(C)=C WFKDPJRCBCBQNT-UHFFFAOYSA-N 0.000 description 1
- QRWZCJXEAOZAAW-UHFFFAOYSA-N n,n,2-trimethylprop-2-enamide Chemical compound CN(C)C(=O)C(C)=C QRWZCJXEAOZAAW-UHFFFAOYSA-N 0.000 description 1
- YPHQUSNPXDGUHL-UHFFFAOYSA-N n-methylprop-2-enamide Chemical group CNC(=O)C=C YPHQUSNPXDGUHL-UHFFFAOYSA-N 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- FSBTYDWUUWLHBD-UDXTWCDOSA-N nafarelin acetate hydrate Chemical compound O.CC(O)=O.C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 FSBTYDWUUWLHBD-UDXTWCDOSA-N 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000001451 organic peroxides Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 208000028241 peripheral precocious puberty Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000002685 polymerization catalyst Substances 0.000 description 1
- 208000001061 polyostotic fibrous dysplasia Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- YPVDWEHVCUBACK-UHFFFAOYSA-N propoxycarbonyloxy propyl carbonate Chemical compound CCCOC(=O)OOC(=O)OCCC YPVDWEHVCUBACK-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000007717 redox polymerization reaction Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000010106 rotational casting Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000010009 steroidogenesis Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940036197 supprelin Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940086546 synarel Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- BWSZXUOMATYHHI-UHFFFAOYSA-N tert-butyl octaneperoxoate Chemical compound CCCCCCCC(=O)OOC(C)(C)C BWSZXUOMATYHHI-UHFFFAOYSA-N 0.000 description 1
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940033942 zoladex Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- H05K999/99—
-
- Y10S514/899—
Definitions
- the present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist in order to treat central precocious puberty (CPP).
- GnRH gonadotropin-releasing hormone
- CPP central precocious puberty or premature puberty. This condition is evident when girls under the age of eight years and boys under the age of nine years develop signs of sexual maturity, such as the early onset of secondary sexual characteristics, increase in growth rate, advancement of skeletal age beyond chronological age. Signs or symptoms of CPP include, but are not limited to, the development of secondary sex characteristics such as breasts, testicle growth, or pubic hair.
- True precocious puberty is the result of premature initiation of the function of the hypothalamic-pituitary axis. Premature release of the luteinizing hormone releasing hormone (LHRH) by the hypothalamus triggers secretion of the pituitary gonadotropin hormones. As a consequence, the gonads function at an inappropriately early age.
- Precocious puberty per se has many subdivisions: isosexual, heterosexual, gonadotropin-dependent (true precocious puberty), gonadotropin-independent, male-limited (familial testotoxicosis), cerebral, central, and idiopathic (unknown) precocious puberty. Precocious puberty is also known as familial testotoxicosis, gonadotropin-independent familial sexual precocity, and pubertas praecox.
- precocious puberty In the majority of cases of precocious puberty, the cause is unknown. In some instances, the pituitary signals the ovaries and testicles to make female and male hormones at an earlier than usual time. In other cases, signs of puberty occur prematurely because of abnormalities in the ovaries, testicles, or adrenal glands. Tests are usually necessary to determine whether the cause of precocious puberty is in the brain or in another area of the body. Usually precocious puberty is idiopathic (unknown cause). In some instances, it is due to an endocrine disorder.
- Cerebral precocious puberty is associated with a brain abnormality, for example a tumor of the central nervous system, including hypothalamic hamartomas, infections, head trauma, hydrocephalus, or hypothyroidism.
- Precocious puberty may also be a feature of McCune-Albright syndrome, neurofibromatosis, Russell-Silver syndrome and disorders of the adrenal glands. Affected individuals may encounter psychological problems due to their accelerated growth and may feet alienated from their peers. They may exhibit increased aggressiveness and hyperactivity.
- Male-limited precocious puberty (familial testotoxicosis) is considered hereditary.
- Cerebral precocious puberty differs in cause but mimics true precocious puberty.
- Central precocious puberty is attended by changes that concern the central nervous system.
- Gonadotropin-dependent precocious puberty is marked by high gonadotropin levels in girls.
- Gonadotropin-independent precocious puberty usually affects boys, who have low levels of gonadotropin.
- Idiopathic precocious puberty is associated with BEG (Elecroencephalogram) irregularities in girls. The cause of the unusual brain waves is unclear.
- Treatments that affect the hypothalamic-pituitary-gonadal axis can effectively reduce hormones to pre-pubertal levels. This may arrest and prevent further development of secondary sex characteristics. Reduction of gonadotropins will allow for normal physical and psychological growth and development. Natural maturation occurs when gonadotropins return to pubertal levels following discontinuation of treatment.
- GnRH (also referred to as luteinizing hormone-releasing hormone (LH-RH)) acts on the anterior pituitary gland to effect release of hormones that affect activity of the reproductive organs.
- GnRH is produced by the hypothalamic region of the brain and controls the reproductive cycle by acting on the anterior pituitary gland to affect release of luteinizing hormone (LH) and follicular stimulating hormone (FSH), which in turn act on the gonads to stimulate the synthesis of steroid hormones and to stimulate gamete maturation.
- LH luteinizing hormone
- FSH follicular stimulating hormone
- the natural GnRH peptide is a hydrophilic decapeptide.
- the monthly injections are painful, expensive, and inconvenient (monthly visits to the clinic nurse or physician).
- gonadotropin suppression is not sustained by a monthly schedule of injections and the GnRH analog needs to be administered at 3-week or even 2-week intervals (1-3).
- the daily dose of histrelin for treatment of CPP is typically about 10 ⁇ g/kg/day, which is equivalent to about 300 to about 600 ⁇ g histrelin per day.
- Histrelin is a synthetic nonapeptide agonist of the naturally occurring GnRH. Initially the drug stimulates release of GnRH; however, chronic use desensitizes responsiveness of the pituitary gonadotropin, causing a reduction in ovarian and testicular steroidogenesis.
- the subject of the present invention is a drug delivery device useful in a method for controlled delivery of GnRH agonists, preferably histrelin, to a patient over an extended period of time.
- This device is useful in the treatment of CPP.
- the present invention provides an implantable drug delivery device containing histrelin.
- the device is a hydrogel polymer material.
- the present invention provides a method of delivery of a therapeutically effective amount of GnRH agonists to a patient. This method involves implanting the patient with a drug delivery device as described herein.
- the present invention provides for a method of obtaining immediate release of GnRH agonist upon implantation in a patient.
- the GnRH agonist such as histrelin
- the GnRH agonist is released following implantation to achieve therapeutically effective amounts of histrelin in vivo to treat CPP.
- the present invention provides for a method of preventing loss of GnRH agonist from an implant during storage.
- FIG. 1 is a graph showing the linear relationship between the equilibrium water content vs. the weight percent content of hydroxypropyl methacrylate (HPMA) units in crosslinked HEMA/HPMA polymers at their maximum state of hydration.
- HPMA hydroxypropyl methacrylate
- FIG. 2 is a graph of the release profiles of various histrelin implants of the present invention.
- FIG. 4 is a graph of the Breast Tanner Scale at pretreatment and 9 months following insertion of an histrelin implant of the present invention.
- FIG. 5 is a graph of Height Velocity at pretreatment and 9 months following insertion of an histrelin implant of the present invention.
- FIG. 6 is a graph of the ratio of bone age:chronologic age at pretreatment and 9 months following insertion of an histrelin implant of the present invention.
- the term “about” means plus or minus 10% of the numerical value of the number with which it is being used. For example about 50% means in the range of 45%-55%.
- Controlled release or “controlled release formulation” refers to a formulation designed to consistently release a predetermined, therapeutically effective amount of drug or other active agent such as a polypeptide or a synthetic compound below toxic levels over an extended period of time, with the result being a reduction in the number of treatments necessary to achieve the desired therapeutic effect.
- the amount of the drug or active agent in the implantable formulations according to embodiments of the present invention establish a therapeutically effective plasma concentration of the drug over a period of 1 month or longer.
- a controlled formulation would decrease the number of treatments necessary to achieve the desired effect in terms of decreased estradiol levels or testosterone levels, or an improvement in symptoms associated with central precocious puberty.
- the controlled release formulations of the present invention achieve a desired pharmacokinetic profile in a subject, preferably commencement of the release of the active agent substantially immediately after placement in a delivery environment, followed by consistent, sustained, preferably zero-order or near zero-order release of the active agent.
- patient and “subject” mean all animals including humans. Examples of patients or subjects include humans, cows, dogs, cats, goats, sheep, and pigs.
- pharmaceutically acceptable salts, esters, amides, and prodrugs refers to those carboxylate salts, amino acid addition salts, esters, amides, and prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.
- prodrug refers to compounds that are rapidly transformed in vivo to yield the parent compounds of the above formula, for example, by hydrolysis in blood.
- a thorough discussion is provided in T. Higuchi and V. Stella, “Pro-drugs as Novel Delivery Systems,” Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.
- salts refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed.
- Representative salts include the acetate, hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate mesylate, glucoheptonate, lactobionate and laurylsulphonate salts, and the like.
- alkali and alkaline earth metals such as sodium, lithium, potassium, calcium, magnesium, and the like, as well as non-toxic ammonium, tetramethylammonium, tetraethylammonium, methlyamine, dimethlyamine, trimethlyamine, triethlyamine, ethylamine, and the like.
- Treatment refers to the administration of medicine or the performance of medical procedures with respect to a patient, for either prophylaxis (prevention) or to cure the infirmity or malady in the instance where the patient is afflicted.
- a “therapeutically effective amount” is an amount sufficient to decrease, prevent, or ameliorate the symptoms associated with a medical condition. In the context of hormonal therapy it can also mean to normalize body functions or hormone levels in disease or disorders.
- a therapeutically effective amount of a controlled release formulation of histrelin is a predetermined amount calculated to achieve the desired effect, e.g., to effectively decrease estradiol levels or testosterone levels in a patient or decrease the symptoms of central precocious puberty.
- the novel drug delivery device of the invention is designed for implantation into the body of the animal to which the histrelin formulation is to be delivered.
- the drug delivery devices of the invention are desirably implants containing histrelin in a reservoir, optionally together with another active agent and/or a pharmaceutically acceptable carrier.
- Such reservoir devices may be composed of hydrophobic or hydrophilic polymers, co-monomers, metals, or other suitable materials.
- the drug delivery devices may be hydrogels, or other polymeric or co-monomer materials, made up of a matrix having histrelin and any other optional active agents or carriers interspersed throughout.
- the histrelin is dispersed homogeneously throughout the matrix.
- suitable implants are known to those of skill in the art and may be readily selected.
- novel implant drug delivery devices of the invention are highly useful in the controlled, sustained release of histrelin to animals, e.g., humans, sheep, dogs, cats, turkeys, cattle, etc.
- histrelin and any other agents employed in the drug delivery devices of the invention will depend not only on the desired daily dose but also on the number of days that dose level is to be maintained. While this amount can be calculated empirically, the actual dose delivered is also a function of any interaction with materials and the carrier, if employed in the device.
- the drug delivery device may contain a pharmaceutically acceptable carrier which may be in the form of suspending media, solvents, aqueous systems, and solid substrates or matrices. These carriers are known to those of skill in the art and are not intended to be a limitation on the present invention.
- One aspect of the invention is a controlled release pharmaceutical composition
- a controlled release pharmaceutical composition comprising histrelin acetate in a controlled release hydrogel device.
- the composition of the present invention is capable of providing, upon administration to a patient, a release profile of histrelin extending over at least 2 months, preferably at least about 6 months or more.
- the histrelin may be released over a period of about 18 months to about 2 years.
- histrelin is contained within the hydrogel and the formulation releases a therapeutically effective amount of histrelin over an extended period of time.
- a therapeutically effective amount is an amount of histrelin, preferably histrelin acetate, that when administered to a patient or subject, ameliorates a symptom of central precocious puberty.
- the formulation may further include pharmaceutically acceptable excipients.
- the concentration of histrelin in the patient's plasma over time may extend over a period of at least 2 months, preferably about 6 months or more. In a further embodiment, the histrelin may be released over a period of about 18 mouths to about 2 years.
- the compositions may provide a mean plasma concentration of histrelin of about 0.2 ng/ml to about 2 ng/ml.
- the compositions may provide a mean plasma concentration at steady state of histrelin in a human patient of from about 0.4 ng/ml to about 0.6 ng/ml. Steady state is the point at which the amount of drug administered over a dosing interval equals the amount of drug being eliminated over that same period.
- the hydrogel is a homogeneous homopolymer or copolymer having a predetermined equilibrium water content (EWC) value formed by the polymerization of a mixture of ethylenically unsaturated monomer A and ethylenically unsaturated monomer B, for example, 2-hydroxyethyl methacrylate (HEMA) and hydroxypropyl methacrylate (HPMA).
- EWC equilibrium water content
- the predetermined EWC may be calculated by determining the EWC values of the hydrogel homopolymer of hydrophilic monomer A (homopolymer A) and the hydrogel homopolymer of hydrophilic monomer B (homopolymer B); determining the relationship of the EWC values of the homogeneous copolymers AB versus the chemical composition of said copolymer AB; selecting the targeted EWC value and determining the chemical composition of copolymer AB having the targeted EWC value; forming a polymerizable mixture of monomer A and monomer B in amounts sufficient to yield copolymer AB having the targeted EWC value; and effect the polymerization reaction to yield copolymer AB characterized by the targeted EWC value.
- Liquid polymerizable material useful in the hydrophilic products include a wide variety of polymerizable hydrophilic, ethylenically unsaturated compounds, in particular, hydrophilic monomers such as the monoester of an acrylic acid or methacrylic acid with a polyhydroxy compound having an esterifiable hydroxyl group and at least one additional hydroxyl group such as the monoalkylene and polyalkylene polyols of methacrylic acid and acrylic acid, e.g., 2-hydroxyethyl methacrylate and acrylate, diethylene glycol methacrylate and acrylate, propylene glycol methacrylate and acrylate, dipropylene glycol methacrylate and acrylate, glycidyl methacrylate and acrylate, glyceryl methacrylate and acrylate, and the like; the 2-alkenamides, e.g., acrylamide, methacrylamide, and the like; the N-alkyl and N,N-dialkyl substitute
- hydrophilic monomers are employed in the polymerization reaction.
- the type and proportion of monomers are selected to yield a homogeneous polymer, preferably a crosslinked homogeneous polymer, which on hydration possesses the desired EWC value for the contemplated application or use.
- this value can be predetermined by preparing a series of copolymers using different monomer ratios, e.g., mixtures of HEMA and HPMA of varying ratios, ascertaining the EWC values of the copolymers, and plotting the relationship of % HPMA (or % HEMA) units in the HPMA/HEMA copolymers vs. weight percent EWC of the copolymers.
- the polymerization of certain hydrophilic monomeric mixtures may result in homogeneous hydrophilic copolymers which dissolve, to a varying extent, in an aqueous medium.
- a small amount, e.g., up to 3 percent, of a copolymerizable polyethylenically unsaturated crosslinking agent can be included in the monomeric mixture to obtain homogeneous crosslinked copolymers which are water-insoluble as well as water-swellable.
- Slightly crosslinked homopolymer of HEMA has a EWC value of about 38%.
- Crosslinked copolymers of HEMA and HPMA have EWC values below 38%.
- crosslinked copolymers of HEMA and acrylamide exhibit EWC values above 38 w/%, e.g., upwards to approximately 75 weight %, and higher. Therefore, depending on the useful or effective elution rate of the active compound. e.g., drug, that is required of a hydrogel delivery system for a particular application, one skilled in the art, by following the teachings disclosed herein, can tailor-make copolymer hydrogel membranes which will elute the drug at the required rate.
- Preferred copolymers contain about 15 to 70 weight % of HEMA units and from about 85 to 30 weight % of units of a second ethylenic monomer and possess predetermined EWC values in the range of from about 20 to about 75%, preferably 25%.
- Highly preferred homogenous copolymers are those made from hydrophilic monomeric mixtures containing from about 80 weight % HPMA, and from about 20 weight % HEMA.
- the mixture may further contain a small amount of a polyethylenically unsaturated crosslinking agent, e.g., trimethylolpropane trimethacrylate (“TMPTMA”).
- TMPTMA trimethylolpropane trimethacrylate
- Various aspects of the invention include homogeneous hydrophilic copolymers whose homogeneous polymer structure is formed via the polymerization of a mixture of hydrophilic monomers described previously; and the drug delivery device which utilize the homogeneous polymer cartridges in the delivery system.
- the polymerization of a mixture of hydrophilic monomers and hydrophobic monomers yields heterogeneous polymers.
- hydrophobic segments are present in the polymer, the interfacial free energy increases thus enhancing protein adsorption and mineralization after implantation in an animal.
- Hydrogels of polyHEMA were measured to have interfacial free energy close to zero. According to the interfacial free energy interpretation, hydrogels of strictly hydrophilic components would strongly appear to be biocompatible with body tissue.
- Slightly crosslinked polyHEMA is a homogeneous, hydrophilic “homopolymer” (disregarding the relatively small quantities of polymerized crosslinking agent therein) of relatively fixed characteristics or values. Techniques of altering the “homopolymer” polyHEMA to impart to it additional characteristics or properties are difficult, time-consuming, and oftentimes result in erratic property behavior. On the other hand, mixtures of HEMA with varying quantities of other polymerizable hydrophilic comonomer(s) can be polymerized to give predictable homogeneous hydrophilic copolymers having (predetermined) tailor-made properties.
- Useful crosslinking agents which can be included in the polymerizable reaction medium include, for example, the polyethylenically unsaturated compounds having at least two polymerizable ethylenic sites, such as the di-, tri- and tetra-ethylenically unsaturated compounds, in particular, the tri-unsaturated crosslinking agents with/without the di-unsaturated crosslinking compounds, for example, divinylbenzene, ethylene glycol dimethacrylate and diacrylate, propylene glycol dimethacrylate and diacrylate; and the di-, tri- and tetra-acrylate or methacrylate esters of the following polyols: triethanolamine, glycerol, pentaerythritol, 1,1,1-trimethylolpropane; and others.
- the polyethylenically unsaturated compounds having at least two polymerizable ethylenic sites such as the di-, tri- and tetra-eth
- the polymerization reaction can be carried out in bulk or with an inert solvent.
- suitable solvents include water; organic solvents such as water-soluble lower aliphatic monohydric alcohols as well as polyhydric alcohols, e.g., glycol, glycerine, dioxane, etc.; and mixtures thereof.
- Compounds useful in the catalysis of the polymerizable ethylenically unsaturated compounds include the free-radical compounds and/or initiators of the type commonly used in vinyl polymerization such as the organic peroxides, percarbonates, hydrogen peroxides, and alkali metal sulfates.
- Illustrative examples include cumene hydroperoxide, t-butyl hydroperoxide, benzoyl peroxide, bis(4-t-butylcyclohexyl) peroxydicarbonate, hydrogen peroxide, 2,4-dichlorobenzoyl peroxide, acetyl peroxide, di-n-propyl peroxydicarbonate, di-t-butyl peroxide, di-sec-butyl peroxydicarbonate, ammonium sulfate, potassium sulfate, and sodium sulfate.
- a preferred catalyst is one which is effective at moderately low temperature such as at about 20°-80° C., such as tert-butyl peroctoate, benzoyl peroxide, and di(secbutyl) peroxydicarbonate.
- a conventional redox polymerization catalyst can also be employed.
- polymerization of the ethylenic compounds can be effected using radiation, e.g., U.V., X-Ray, gamma radiation, microwave, or other well-know forms of radiation.
- a preferred catalyst for U.V. cure is benzoin methyl ether.
- Catalysts and/or initiators and/or radiation are employed in a catalytically effective amount to optimize the polymerization reaction.
- small cylindrically shaped implants containing within their core histrelin, preferably histrelin acetate, and optionally, a pharmaceutically acceptable carrier.
- the membrane thickness (between the interior and exterior surfaces) of the implant is substantially uniform, and serves as a rate-limiting barrier for the release of the contained agent.
- Such implants can be plasticized or hydrated and reshaped into other geometrically shaped articles for use in various medical applications.
- the hydrophilic implant as a xerogel readily absorbs water. In a hydrated state it is referred to as a hydrogel. In either form, it is biocompatible and non-toxic to the host and non-biodegradable. It is, of course, water-swellable and water-insoluble. When the hydrogel attains its maximum level of hydration, the water content of the hydrogel is referred to as “equilibrium water content”.
- the percent water content of the hydrogel is determined as follows:
- the release profile (delay time, release rate, and duration) is determined; the hydrophilic polymeric material is identified; and the diffusivity of the active agent through it (as a rate-limiting membrane) is measured.
- the hydration profile of the rate-limiting membrane for a given active agent may be readily determined by preparing a film of the selected polymer and subjecting it to a diffusion study, using a two compartment vertical glass cell, as is well known in the art.
- the diffusion coefficient and the water content at which diffusion begins are determined.
- a series of membranes is prepared from various polymers. The membranes are then hydrated to their capacity and their equilibrium water contents are measured. The fully hydrated membranes are placed in the two-compartment, vertical glass cells to measure and plot the diffusion of the macromolecular composition through the membrane materials at the various equilibrium water contents.
- the equilibrium water content of the most hydrated membrane through which no diffusion is detected is the % H d for the system being tested. This can be accomplished by plotting a curve of the permeability vs. equilibrium water content.
- dQ/dt is the flux through the membrane material ( ⁇ g/hr); it is measured as the slope of the linear part of the curve of cumulative transport versus time; wherein A is the area of the membrane (cm 2 ); wherein P is the membrane's permeability coefficient (cm 2 /hr), or DK d , wherein D is the diffusivity of the membrane (cm 2 /hr), and K d is the partition coefficient for the membrane/donor solution; wherein 1 is the membrane thickness as measured at the end of the experiment (cm); and wherein C d is the concentration of the donor solution ( ⁇ g/cm 3 ).
- the release delay profile is then determined.
- Another series of polymeric membranes can be prepared, again varying the amounts of crosslinker and monomers. These membranes are then hydrated, but only partially, i.e., to a water content less than or equal to % HL. The partially hydrated membranes are placed in two-compartment vertical glass cells to measure and plot the diffusion of the active compound through the membranes versus time. Buffer solutions for the donor and receptor cells may be selected to contact the partially hydrated membranes and further hydrate them at approximately the same rate at which they will hydrate in the delivery environment. The time between commencement of the diffusion study, i.e., addition of the active agent to the donor cell, and the detection of a pharmaceutically effective concentration of the active agent in the receptor cell is the release delay time for that combination of polymer and initial percent hydration.
- the total amount of active agent to be delivered must be determined. This is the product of the desired daily dosage and the duration of delivery. In preferred embodiments, the duration of delivery is at least about 2 months, more preferably about 6 months or longer and the desired daily dosage is, for example, about 60 ⁇ g to about 70 ⁇ g of histrelin.
- the volume of the cylindrical reservoir (core) of a cylindrically-shaped device is equal to ⁇ r i 2 h wherein r i is the radius of the reservoir and h is its height.
- the formula for steady state release from a cylinder is:
- r o is the outside radius of the cylindrical device; and wherein C d is the concentration of drug in the donor solution, i.e., the carrier. Steady state release is obtained when C d is maintained at saturation.
- the thickness of the membrane needed for the desired sustained release is, therefore, r o ⁇ r i .
- the amount of active agent employed will depend not only on the desired daily dose but also on the number of days that dose level is to be maintained. While this amount can be calculated empirically, the actual dose delivered is also a function of any interaction with materials and the carrier, if employed in the device.
- the novel formulation of the present invention may contain a pharmaceutically acceptable carrier which may include, but is not limited to, suspending media, solvents, aqueous systems, and solid substrates or matrices.
- Suspending media and solvents useful as the carrier include, for example, oils such as silicone oil (particularly medical grade), corn oil, castor oil, peanut oil and sesame oil; condensation products of castor oil and ethylene oxide; liquid glyceryl trieters of a lower molecular weight fatty acid; lower alkanols; glycols; polyalkylene glycols.
- oils such as silicone oil (particularly medical grade), corn oil, castor oil, peanut oil and sesame oil
- condensation products of castor oil and ethylene oxide condensation products of castor oil and ethylene oxide
- liquid glyceryl trieters of a lower molecular weight fatty acid lower alkanols
- glycols glycols
- polyalkylene glycols polyalkylene glycols.
- the aqueous systems include, for example, sterile water, saline, dextrose, dextrose in water or saline, and the like.
- the presence of electrolytes in the aqueous systems may tend to lower the solubility of the macromolecular drug in them.
- the solid substrates or matrices include, for example, starch, gelatin, sugars (e.g., glucose), natural gums (e.g., acacia, sodium alginate, carboxymethyl cellulose), and the like.
- the carrier may also contain adjuvants such as preserving stabilizing, wetting and emulsifying agents, and the like.
- the hydrating liquid useful in the practice of the invention is typically a liquid simulating the environment in which the active compound will be released, e.g., body fluid, sterile water, tear fluid, physiological saline solution, phosphate buffer solution, and the like. While liquids other than water are useful as the hydrating liquid, the degree to which a hydrophilic membrane is hydrated is referred to as its “water content”.
- copolymer AB or “copolymer AB consists essentially of monomer A units and monomer B units” is meant that the addition copolymerization of monomer A and monomer B has been effected through the polymerizable ethylenic bond of the said monomers.
- monomer A is 2-hydroxyethyl methacrylate and monomer B is N-methylacrylamide
- copolymer AB contains recurring monomer A units and recurring monomer B units.
- copolymer includes polymers made by polymerizing a mixture of at least two ethylenically unsaturated monomers.
- HEMA unit(s) the structure
- HEMA 2-hydroxyethyl methacrylate
- HPMA unit(s) is meant the structure
- HPMA hydroxypropyl methacrylate
- a pharmaceutical formulation of the present invention comprises a formulation of histrelin within a mixture of HEMA and HPMA copolymer, preferably about 45% HEMA and 55% HPMA.
- the pharmaceutical formulation comprises about 25 to about 150 milligrams of histrelin, preferably about 35-45 milligrams of histrelin base.
- the formulation may further comprise between about 0.5% to about 20% excipients.
- the formulation further comprises about 2% stearic acid.
- hydrogels are suited as Implantable delivery vehicles for use in delivery of histrelin according to the present invention.
- One hydrogel is prepared by mixing about 60 weight percent to about 95 weight percent comonomers, at least one of which is hydrophilic, and sufficient amounts of a crosslinker and a liquid diffusion enhancer which is miscible with the comonomers, to yield a homogenous copolymer hydrogel having the equilibrium water content (EWC) value in the range from about 20% to about 85%. More preferably, homogenous copolymer hydrogel has a EWC value in the range from about 25% to about 35%.
- EWC equilibrium water content
- another hydrogel is prepared by mixing about 40 weight percent to about 95 weight percent comonomers, at least one of which is hydrophilic, and sufficient amounts of a crosslinker and optionally a liquid diffusion enhancer which is miscible with the comonomers, to yield a homogenous copolymer hydrogel having the equilibrium water content (EWC) value in the range from about 20% to about 85%, more preferably from about 25% to about 35%.
- EWC equilibrium water content
- the polymerizable liquid mixture may also contain about 1 weight percent to about 50 weight percent diffusion enhancer which may be readily selected from among C1-C4 alkyl alcohol, allyl alcohol, tetrahydrofuryl alcohol, cyclohexyl alcohol, diethylene glycol, polyethylene glycols, glycerol, acetone, ethylene glycol monomethyl ether, ethylene glycol monoethyl ether. glyceryl isopropylidene ether dioxane, tetrahydrofuran; ethyl acetate; dimethyl sulfoxide; water, and mixtures thereof.
- the crosslinker and comonomers may be readily selected by one of skill in the art.
- Hydrogels and methods of preparation are generally described in International Patent Application Number PC/US00/01664, filed Jan. 26, 2000 for “Hydrogel Compositions Useful for the Sustained Release of Macromolecules and Methods of Making Same.”
- Other suitable hydrogels may be readily selected by one of skill in the art. See, e.g., U.S. Pat. Nos. 5,266,325; 4,959,217; and 5,292,515.
- Another particularly desirable hydrogel is prepared by mixing about 40 weight percent to about 95 weight percent comonomers, at least one of which is hydrophilic, and sufficient amounts of a crosslinker and optionally a liquid diffusion enhancer which is miscible with the comonomers, to yield a homogenous copolymer hydrogel having the equilibrium water content (EWC) value in the range from about 20% to about 85%. More preferably, homogenous copolymer hydrogel has a EWC value in the range from about 25% to about 35%.
- EWC equilibrium water content
- the hydrogel comprises 2-hydroxyethyl methacrylate (HEMA) and hydroxypropyl methacrylate (HPMA).
- the hydrogel may also further comprise a crosslinking agent, such as, for example (TMPTMA).
- TMPTMA crosslinking agent
- the hydrogel comprises about 45% of HEMA, about 54.5% HPMA and about 0.5% TMPTMA.
- a delivery device capable of providing a sustained release of a therapeutically effective amount of GnRH agonist.
- the controlled release is achieved of a period of time of at least 6 months or more, more preferably about 1 to about 2 years.
- the delivery device comprises a hydrogel, wherein the composition of the hydrogel is based upon the desired daily dose and release profile.
- a delivery device capable of providing controlled release of about 60 ⁇ g to about 70 ⁇ g of histrelin per day is provided. In a more preferred embodiment, the delivery device provides about 65 ⁇ g of histrelin per day.
- the diffusion of the drug occurs through water channels in the hydrogel. Controlling the water content of the hydrogel allows for manipulation of the release profile of the agent within the hydrogel.
- the release may also be manipulated by the geometry of the drug delivery device, including, for example, the area, wall thickness and diameter. Treatment of particular diseases or conditions may require higher or lower therapeutic levels or differing release profiles, which may be achieved through the design of the drug delivery device of the present invention.
- the hydrating liquid useful in the hydrogels used in the invention is typically a liquid simulating the environment in which the active compound will be released, e.g., body fluid, sterile water, tear fluid, physiological saline solution, phosphate buffer solution, and the like. While liquids other than water are useful as the hydrating liquid, the degree to which a hydrophilic membrane is hydrated is referred to as its “water content.”
- the implant may be in the form of an osmotic pump, such as described by Alza (see, e.g., U.S. Pat. Nos. 4,285,987 and 5,273,752) or Merck (see, e.g., European Patent No. 314,206), among others.
- the implant device may be composed of a hydrophobic membrane material, such as ethylmethacrylate (EMA) and ethylenevinylacetate (EVA).
- EMA ethylmethacrylate
- EVA ethylenevinylacetate
- Other suitable implant delivery devices include bioresorbable polymer systems (see, e.g., International Patent Application No. WO98/44964, Bioxid and Cellomeda, U.S. Pat. Nos. 5,756,127 and 5,854,382).
- Suitable bioresorbable implant devices have been described in the literature and may be composed of, for example, polyesters, polyanhydrides, or lactic acid/glycolic acid copolymers (see, e.g., U.S. Pat. No. 5,817,343 Alkermes Inc.).
- the devices useful in the invention(s) provide sustained release of histrelin over extended periods of time.
- This time period may range from a month to a year or several years, depending on the desired administration regimen.
- histrelin will be released in daily doses over a period of about 2 months or longer, and preferably over a period of about six months to one year or longer.
- the histrelin may be released over a period of about 18 months to about 2 years. It is to be understood that this time factor is a variable depending on the rate-releasing membrane of choice, its interconnecting pore structure, the solubility of the active compound(s) in the liquid medium, and other considerations well known to those skilled in the art.
- the delivery device is composed of a hydrogel
- it may be prepared such that the hydrogel forms the walls of a cavity which contain the active agent.
- the void in the core is thereafter sealed to prevent leakage into or out of the vesicle.
- this can be accomplished by introducing sufficient polymerizable material into the void to cover the layer of inert material or to substantially or completely fill the void and thereafter effecting a polymerization reaction to form a plug of water-swellable, water-insoluble polymer which seals the opening of the vesicle.
- the hydrophilic polymer plug upon maximum hydration, will have an equilibrium water content value of the hydrophilic vesicle.
- polymerizable material comprising ethylenically unsaturated monomer(s) and desirably crosslinking agent(s)
- a polymer plug grafted to the inner surface of the vesicle can be obtained.
- hydrophilic cartridges are prepared by the rotational casting of polymerizable material in a tubular mold, as described in U.S. Pat. Nos. 5,266,325 and 5,292,515, which are incorporated herein by reference.
- the internal radius of the tube is approximately 1.2 to 1.3 mm, and may be larger.
- the tube is rotated about its longitudinal axis which is maintained parallel to the ground. Rotational speeds are of the order of 2150 rpm, though greater or lesser speeds could be used, e. g., 1000 rpm or less to 3000 rpm and more.
- the tubes are fabricated of polyethylene, polypropylene, glass, or other suitable materials.
- U.V. light at a distance of less than one foot is then directed at the spinning tube for several minutes, e.g., about 7 minutes, to polymerize the mixture to the shaped product.
- the shaped product is cured and annealed as follows: Thermal Cure: 60 minutes at 65° C.; Postcure: 30 minutes at 95° C.; Annealing: 30 minutes at 115° C. with gradual cooling to about 25° C.
- the cartridge may be of any desired combination of dimensions.
- the internal radius may be about 0.98 mm; the external radius may be about 1.3 mm; and the length may be about 25 mm, or of larger or smaller dimensions, as desired.
- Such objects in a hydrated state or plasticized with a non-toxic biocompatible material, can be formed into desired shapes.
- a ring shape for use as pessaries, surgical implants, etc.
- Yet other drug delivery devices and implant shapes may be prepared using techniques known to those of skill in the art or purchased from commercial sources.
- the length of the implantable delivery device is about 32-37 mm, the outside diameter is about 3-3.5 mm, the cartridge walls are about 0.5 mm and the cavity diameter is about 2-2.5 mm.
- the invention provides for a method of delivering histrelin, alone or in combination with other active agents, upon implantation in a patient.
- the hydrogel delivery device of the present invention is hydrated with a hydrating liquid prior to implantation in the patient, so as to provide release of histrelin upon implantation.
- a method of inhibiting release of histrelin prior to implantation is provided.
- the hydrogel implant delivery device of the present invention is stored in a hydrating liquid prior to implantation in the patient, so as to limit release of histrelin from the implant prior to implantation.
- the hydrating liquid is sodium chloride solution.
- the invention provides a method of delivering histrelin, alone or in combination with other active agents, to a veterinary or human patient in need thereof.
- a patient has a disease or condition such as central precocious puberty.
- one or more delivery devices as described herein can be implanted subcutaneously in an animal by perforation.
- Such devices are characterized by a length of 10 to 50 mm, or less (e.g., 6 to 9 mm), an external diameter of 2 to 5 mm, or less (e.g., 1.5 to 1.9 mm).
- the dimensions of the device e.g., a cartridge
- Animals such as sheep, cows, goats, cattle, and large animals, in general, can tolerate implantation by perforation of larger dimensional drug delivery devices.
- Implantation can be effected by other means, e.g., open surgery.
- the drug delivery device is a biodegradable matrix, which is bioresorbed and eliminated from the body following completion of the course of therapy, e.g., at least about 2 months, or more preferably about 12 months or longer.
- a selected delivery device may be removed by surgical means.
- a method of treating a disease associated with a hormonal disorder may include administering histrelin and maintaining a plasma concentration of histrelin of about 0.2 ng/ml to about 2 ng/ml and maintaining a plasma concentration of histrelin at steady state between about 0.4 ng/ml and about 0.6 ng/ml over an extended period of time, preferably at least about 2 months, and more preferably about 6 months or longer.
- Such hormonal disorders include CPP or the like.
- the method may comprise administering one or more delivery devices comprising a hydrogel of about 45% of HEMA, about 54.5% HPMA, about 0.5% TMPTMA and histrelin acetate.
- One embodiment is a method of decreasing estradiol levels or testosterone levels by administering histrelin and maintaining a steady state plasma concentration of histrelin between about 0.4 ng/ml and about 0.6 ng/ml, over an extended period of time, preferably at least about 2 months, and more preferably about 6 months or longer.
- Another embodiment is a method of decreasing symptoms of CPP by administering histrelin and maintaining a plasma concentration of histrelin between about 02 ng/ml to about 2 ng/ml over an extended period of time, preferably at least about 2 months, and more preferably about 6 months or longer.
- Another embodiment is a method of treating CPP comprising administering at least one hydrogel implant of the present invention, or two or more hydrogel implants of the present invention.
- each hydrogel of the two hydrogel implants administered may contain between about 25 to about 150 milligrams of histrelin acetate, preferably about 40 to about 90 milligrams of histrelin acetate, more preferably about 50 milligrams of histrelin acetate and release a therapeutically effective amount of histrelin over a period of at least two months, preferably six months or longer.
- a method of treating CPP comprises administering one or more implants comprising a hydrogel and histrelin.
- the hydrogel implants contain about 50 milligrams of histrelin acetate and release from about 60 ⁇ g to about 70 ⁇ g of histrelin acetate substantially upon implantation for a period of at least 2 months, more preferable for about 1 year.
- Another aspect is a therapeutic composition of a hydrogel and histrelin, wherein, upon implantation, histrelin is released at a rate that provides and/or maintains a C ss of about 0.2 ng/ml to about 2 ng/mi.
- a further embodiment is a therapeutic composition of a hydrogel and histrelin, wherein, upon implantation, the histrelin is released at an average rate of from about 60 to about 70 ⁇ g/day, preferably an average of about 65 ⁇ g daily over an extended period of time, preferably at least about two months, more preferably about six months or longer.
- Another embodiment is a controlled release formulation comprising histrelin and a hydrophilic polymer, which permits release of the histrelin at a rate of about 60 ⁇ g to about 70 ⁇ g per day over about six months or longer in vitro.
- the hydrophilic polymer of the formulation permits release of histrelin at an average rate of about 65 ⁇ g per day in vitro.
- a controlled release formulation comprising histrelin and a hydrophilic polymer is provided that releases from about 140 ⁇ g to about 40 ⁇ g per day over about six months or longer, more preferably about 135 ⁇ g to about 60 ⁇ g per day over about six months or longer.
- the amount of a pharmaceutically acceptable histrelin, salt, solvated, or prodrug thereof included in the pharmaceutical composition of the present invention will vary, depending upon a variety of factors, including, for example, the specific histrelin used, the desired dosage level, the type and amount of hydrogel used, and the presence, types and amounts of additional materials included in the composition.
- the amount of histrelin, or a derivative thereof in the formulation varies depending on the desired dose for efficient drug delivery, the molecular weight, and the activity of the compound.
- the actual amount of the used drug can depend on the patient's age, weight, sex, medical condition, disease or any other medical criteria. The actual drug amount is determined according to intended medical use by techniques known in the art.
- the pharmaceutical dosage formulated according to the invention may be administered about once every six months as determined by the attending physician.
- the histrelin is formulated in the implant or other pharmaceutical composition in amounts of about 25 milligrams to about 150 milligrams, preferably about 40 to about 90 milligrams of histrelin.
- the amount of histrelin in the composition is formulated to release from about 60 ⁇ g to about 70 ⁇ g of histrelin daily and maintain therapeutic levels in the patient's blood at about 0.2 ng/ml to about 2 ng/ml over an extended period of time.
- hydrogel device in which histrelin is contained provides a controlled release of histrelin into the plasma of the patient.
- Hydrogels suitable for controlling the release rate of histrelin for use in the pharmaceutical compositions of the present invention include polymers of hydrophilic monomers, including, but not limited to HPMA, HEMA and the like. Such hydrogels are also capable of preventing degradation and loss of histrelin from the composition.
- a pharmaceutical formulation of the present invention comprises histrelin acetate contained within a hydrophilic copolymer of 2-hydroxyethyl methacrylate and hydroxypropyl methacrylate.
- the copolymer of the pharmaceutical formulation comprises about 45% HEMA and about 55% HPMA.
- the formulation further comprises stearic acid.
- the amount of the hydrogel included in the pharmaceutical composition of the present invention will vary depending upon a variety of factors, including, for example, the specific matrix used, its molecular weight, its hydrophilicity, the type and amount of histrelin used, and the presence, types and amounts of additional materials included in the composition.
- the size, shape and surface area of the implant may also be modified to increase or decrease the release rate of histrelin from the implant.
- the formulations of the present invention exhibit a specific, desired release profile which maximizes the therapeutic effect while minimizing adverse side effects.
- the desired release profile may be described in terms of the maximum plasma concentration of the drug or active agent (C max ) and the plasma concentration of the drug or active agent at steady state (C ss ).
- treatment of CPP or related conditions using the drug delivery devices of the invention may be readily combined with other therapies administered by routes other than through the use of an implantable devices.
- treatment with histrelin according to the invention may be combined with other treatments or therapies.
- Hydrogel implants were prepared in accordance with the present invention.
- about 45% HEMA, 54.5% HPMA and about 0.5% TMPTMA were admixed with 0.3% benzoinmethylether (BME) and 0.1% percadox-16.
- BME benzoinmethylether
- histrelin implants were prepared in accordance with the present invention.
- the histrelin implants comprised about 45% HEMA and about 55% HPMA.
- the resulting hydrogel implants exhibited an equilibrium water content (EWC) of about 29%.
- the implants were prehydrated.
- the release rates were measured over sixty weeks.
- the release profile for the histrelin implants is provided in FIG. 2 .
- Study visits occurred at baseline, 4 weeks (Month 1), 3 months, and then every 3 months for the remainder of the study. Blood samples for determination of histrelin serum concentrations and determination of hormone levels were collected at each clinic visit. GnRH challenge tests were performed with Relefact® LHRH 0.1 mg ( 100 ⁇ g gonadorelin) intravenous injection before the implant insertion, at month 9, and at month 18 for all patients. GnRH challenge tests were also performed at every visit after month 9 for the patients whose implant(s) remained in place after that time. If at any visit there was incomplete hormonal suppression or if the clinical evaluation indicated disease progression, the implant was to be removed and the child offered a new implant.
- the duration of treatment at study entry ranged from less than 2 weeks to 39 months. Eight of the patients had been treated for 7 months or less, one for 18 months, one for 21 months, and one for 39 months.
- the standard treatments were decapeptyl embonate (9 patients), diphereline (1 patient), or both decapeptyl and diphereline (1 patient). These were administered as intramuscular depot injections every 21 to 28 days.
- the histrelin implant was inserted anywhere from 2 days to 1.5 months after the last depot injection.
- the standard GnRH treatment had suppressed estradiol levels to below 73 pmol/L in 10 of the 11 patients at the time of implant insertion. None of these 10 patients bad an estradiol level greater than 73 pmol/L at any evaluation through month 12, i.e., their values remained within the prepubertal range.
- Basal luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels were suppressed due to standard GnRH treatment at baseline and remained suppressed following implant insertion. Suppression of peak LH and FSH responses to GnRH testing was maintained for 9 months following implant insertion in all 11 girls, and for 12 months in the six girls who had their original implants left in place and had GnRH challenge testing at 12 months.
- Table 2 displays the estradiol results for subsets of the patients categorized by the member of implants they received. The suppression of estradiol levels was maintained regardless of whether the patients received one or two implants. Within the group of patients who received one implant, the results were similar regardless of baseline weight.
- Table 3 summarizes the estradiol results after 9 months. Suppression of estradiol levels appeared to be maintained in patients who received new implants at 9 months and also in patients whose original implant(s) remained in place at 9 through 12 months.
- Table 5 shows the mean values and mean changes in LH and FSH for patients categorized the by the number of implants.
- the mean changes in LH were larger for patients with two implants than for those with one implant.
- the subgroup of patients with one implant showed a mean decrease in FSH during the first month of treatment. This decrease was maintained through month 9.
- the subgroup of patients with two implants showed a small mean increase in FSH during the first 9 months of treatment.
- the pattern of changes in LH was similar regardless of baseline weight in the subgroup of patients with one implant.
- the patients who weighed >40 kg at baseline had larger mean decreases in FSH at every evaluation (ranging from ⁇ 0.37 to ⁇ 0.50 mIU/mL) than did those who weighed 540 kg at baseline (ranging from ⁇ 0.13 to ⁇ 0.25 mIU/mL).
- Table 6 summarizes the LH and FSH results after 9 months of treatment. Suppression of LH and FSH levels was maintained in patients who received new implants at 9 months and also in patients whose original implant(s) remained in place at 9 and 12 months.
- GnRH challenge tests were done at month 12 only for patients whose implants were left in place at month 9 (second track). At month 12, these patients continued to show no mean increase in LH and FSH levels in response to administration of LHRH.
- the mean value for IGF-1 was 350.18 ng/mL at baseline and 311.82 ng/mL at month 9, yielding a mean change of ⁇ 38.36 ng/mL.
- the mean value for IGF-BP3 was 5.47 mg/L at baseline and 6.51 mg/L at Month 9, yielding a mean change of 1.04 mg/L.
- FIG. 3A displays the serum histrelin concentrations for each patient with 1 implant (track 1) at all evaluation times and FIG. 3B displays the serum histrelin concentrations for each patient with 2 implants (track 2) at all evaluation times. Histrelin levels remained fairly constant over time for most patients.
- Temperature, blood pressure, heart rate, weight, and height were measured at every evaluation. The mean changes that occurred in temperature, blood pressure, and heart rate were small, showed no time-related trends, and were not clinically meaningful.
- Weight adjusted for age Patient 103 (1.98 at baseline and 1.98 at month 12); Patient 107 (2.41 at baseline and 2.45 at month 12); and Patient 111 (2.10 at baseline and 2.32 at month 12).
- BMI adjusted for age Patient 102 ( ⁇ 2.49 at baseline to ⁇ 1.25 at month 12); Patient 103 (2.04 at baseline and 1.95 at month 12); and Patient 107 (1.88 at baseline and 2.04 at month 12).
- FIG. 5 illustrates the decrease of height velocity during treatment.
- FIG. 6 the bone age to chronologic age ratio was assessed at insertion and at nine months following implantation, as illustrated in FIG. 6 .
- FIG. 4 Shift tables displaying changes in Tanner Stage from screening to each subsequent visit are presented in FIG. 4 .
- two (18%) patients were rated Tanner Stage 2, five (45%) were rated Tanner Stage 3, and four (36%) were rated Tanner Stage 4 for breasts. All of the Stage 4 patients were rated Stage 3 at every evaluation from month 3 onward.
- One Stage 3 patient was rated Stage 2 at every evaluation from month 2 onward.
- Four Stage 3 patients were rated Stage 3 at all evaluations from month 2 to month 9.
- three of those patients were rated Stage 3 whereas the fourth patient (Patient 101) was rated Stage 4.
- the latter patient was the only patient who had an increase in Tanner Stage for breast at any time during the study.
- Tanner Stage 1 At screening, two (18%) patients were rated Tanner Stage 1, five (45%) were rated Stage 2, three (27%) were rated Stage 3, and one (9%) was rated Stage 4 for pubic hair. The only Stage 4 patient was rated Stage 3 at every evaluation from month 1 onward. Of the remaining patients, few had increases in Tanner Stage: one from Stage 1 to 2, two from Stage 2 to 3, and one from Stage 3 to 4.
- Patient 103 was a 10-year-old girl who received two implants. She developed a local infection at the implant site, which resolved in 10 days after treatment with oral antibiotics. At Month 9, she was assigned to the first track and had her two original implants removed. A new implant was inserted in the same incision. A wound infection developed approximately 1 week after the new implant had been inserted. This infection also resolved after treatment with oral antibiotics. Ten days after insertion of the new implant, it was found to be partially extruded from the incision site and was removed. The patient withdrew from the study after the implant was removed. Seven (64%) patients experienced at least one adverse event during the study. The most commonly reported events were conditions related to the implant site and infections. All of the events were rated mild by the investigator.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- This application is a divisional of U.S. patent application Ser. No. 11/155,822, filed Jun. 17, 2005, which claims priority from U.S. Provisional Application Ser. No. 60/580,520 filed Jun. 17, 2004, the contents of which are incorporated by reference in its entirety.
- The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist in order to treat central precocious puberty (CPP).
- There is a wide range of ages at which individuals normally start puberty. Girls usually develop breasts and then pubic hair between the ages of 8 and 13 years. Menstrual periods typically start at 12 to 13 years of age. Girls will often experience moodiness and become more irritable during puberty. Boys normally develop testicular enlargement and then pubic hair between the ages of 9 and 14 years. Underarm and facial hair, as well as deepening of the voice, typically occur between the ages of 13 and 16 years.
- In the United States, an estimated one out of every 10,000 children suffers from central precocious puberty or premature puberty. This condition is evident when girls under the age of eight years and boys under the age of nine years develop signs of sexual maturity, such as the early onset of secondary sexual characteristics, increase in growth rate, advancement of skeletal age beyond chronological age. Signs or symptoms of CPP include, but are not limited to, the development of secondary sex characteristics such as breasts, testicle growth, or pubic hair.
- True precocious puberty is the result of premature initiation of the function of the hypothalamic-pituitary axis. Premature release of the luteinizing hormone releasing hormone (LHRH) by the hypothalamus triggers secretion of the pituitary gonadotropin hormones. As a consequence, the gonads function at an inappropriately early age. Precocious puberty per se has many subdivisions: isosexual, heterosexual, gonadotropin-dependent (true precocious puberty), gonadotropin-independent, male-limited (familial testotoxicosis), cerebral, central, and idiopathic (unknown) precocious puberty. Precocious puberty is also known as familial testotoxicosis, gonadotropin-independent familial sexual precocity, and pubertas praecox.
- In the majority of cases of precocious puberty, the cause is unknown. In some instances, the pituitary signals the ovaries and testicles to make female and male hormones at an earlier than usual time. In other cases, signs of puberty occur prematurely because of abnormalities in the ovaries, testicles, or adrenal glands. Tests are usually necessary to determine whether the cause of precocious puberty is in the brain or in another area of the body. Usually precocious puberty is idiopathic (unknown cause). In some instances, it is due to an endocrine disorder. Cerebral precocious puberty is associated with a brain abnormality, for example a tumor of the central nervous system, including hypothalamic hamartomas, infections, head trauma, hydrocephalus, or hypothyroidism. Precocious puberty may also be a feature of McCune-Albright syndrome, neurofibromatosis, Russell-Silver syndrome and disorders of the adrenal glands. Affected individuals may encounter psychological problems due to their accelerated growth and may feet alienated from their peers. They may exhibit increased aggressiveness and hyperactivity. Male-limited precocious puberty (familial testotoxicosis) is considered hereditary.
- In females, the breasts start to develop before age 8, or menstruation occurs before
age 10, and growth is rapid. In males, onset is beforeage 10; boys grow facial, underarm, and pubic hair, growth, including that of the penis, accelerates; the voice deepens; and behavior becomes more aggressive. Puberty may take place beforeage 3 in some children. Children with precocious puberty are taller than their peers. Since bone maturity is usually hastened in precocious puberty, closure of growth occurs prematurely, and patients are short in stature in adulthood. In isosexual precocious puberty, feminizing signs appear in girls, masculinization in boys. Heterosexual precocious puberty causes signs of masculine characteristics in girls and feminization in boys. Cerebral precocious puberty differs in cause but mimics true precocious puberty. Central precocious puberty is attended by changes that concern the central nervous system. Gonadotropin-dependent precocious puberty is marked by high gonadotropin levels in girls. Gonadotropin-independent precocious puberty usually affects boys, who have low levels of gonadotropin. Idiopathic precocious puberty is associated with BEG (Elecroencephalogram) irregularities in girls. The cause of the unusual brain waves is unclear. - Treatments that affect the hypothalamic-pituitary-gonadal axis can effectively reduce hormones to pre-pubertal levels. This may arrest and prevent further development of secondary sex characteristics. Reduction of gonadotropins will allow for normal physical and psychological growth and development. Natural maturation occurs when gonadotropins return to pubertal levels following discontinuation of treatment.
- GnRH (also referred to as luteinizing hormone-releasing hormone (LH-RH)) acts on the anterior pituitary gland to effect release of hormones that affect activity of the reproductive organs. GnRH is produced by the hypothalamic region of the brain and controls the reproductive cycle by acting on the anterior pituitary gland to affect release of luteinizing hormone (LH) and follicular stimulating hormone (FSH), which in turn act on the gonads to stimulate the synthesis of steroid hormones and to stimulate gamete maturation. The natural GnRH peptide is a hydrophilic decapeptide. Agonist analogs of GnRH may be used to control fertility, for example, low doses of GnRH agonists may stimulate ovulation and larger doses may block ovulation in females and suppress spermatogenesis in males through classic negative feedback principles.
- Conventional treatment of CPP includes administration of GnRH agonists. Synthetic analogues of GnRH agonists are considered to be more effective than the natural agonists. Examples of GnRH agonists include, but not limited to, leuprolide (Lupron Depot®), goserelin (Zoladex®) and histrelin (Supprelin®), buserelin (Suprefact®), nafarelin (Synarel®) and triptorclin (De-capeptyl®, Trelstar Depot®). Many of these formulations involve monthly intramuscular injections of the drug. While usually effective in suppressing gonadotropin secretion, the monthly injections are painful, expensive, and inconvenient (monthly visits to the clinic nurse or physician). In some patients, gonadotropin suppression is not sustained by a monthly schedule of injections and the GnRH analog needs to be administered at 3-week or even 2-week intervals (1-3). For children, the daily dose of histrelin for treatment of CPP is typically about 10 μg/kg/day, which is equivalent to about 300 to about 600 μg histrelin per day.
- Histrelin is a synthetic nonapeptide agonist of the naturally occurring GnRH. Initially the drug stimulates release of GnRH; however, chronic use desensitizes responsiveness of the pituitary gonadotropin, causing a reduction in ovarian and testicular steroidogenesis.
- In view of the foregoing, a method for treating central precocious puberty and therapeutic compositions of GnRH agonists are provided.
- The subject of the present invention is a drug delivery device useful in a method for controlled delivery of GnRH agonists, preferably histrelin, to a patient over an extended period of time. This device is useful in the treatment of CPP.
- Thus, in one embodiment, the present invention provides an implantable drug delivery device containing histrelin. In one particular embodiment, the device is a hydrogel polymer material.
- In a further embodiment, the present invention provides a method of delivery of a therapeutically effective amount of GnRH agonists to a patient. This method involves implanting the patient with a drug delivery device as described herein.
- In another embodiment, the present invention provides for a method of obtaining immediate release of GnRH agonist upon implantation in a patient. Desirably, the GnRH agonist, such as histrelin, is released following implantation to achieve therapeutically effective amounts of histrelin in vivo to treat CPP.
- In a further embodiment, the present invention provides for a method of preventing loss of GnRH agonist from an implant during storage.
- Other aspects and advantages of the invention will be readily apparent form the detailed description of the invention.
- For a fuller understanding of the nature and advantages of the present invention, reference should be had to the following detailed description taken in connection with the accompanying drawings.
-
FIG. 1 is a graph showing the linear relationship between the equilibrium water content vs. the weight percent content of hydroxypropyl methacrylate (HPMA) units in crosslinked HEMA/HPMA polymers at their maximum state of hydration. -
FIG. 2 is a graph of the release profiles of various histrelin implants of the present invention. -
FIG. 3A is a graph of the serum histrelin concentrations for each patient with 1 implant (track 1) at all evaluation times andFIG. 3B is a graph of the serum histrelin concentrations for each patient with 2 implants (track 2) at all evaluation times. -
FIG. 4 is a graph of the Breast Tanner Scale at pretreatment and 9 months following insertion of an histrelin implant of the present invention. -
FIG. 5 is a graph of Height Velocity at pretreatment and 9 months following insertion of an histrelin implant of the present invention. -
FIG. 6 is a graph of the ratio of bone age:chronologic age at pretreatment and 9 months following insertion of an histrelin implant of the present invention. - Before the present compositions and methods are described, it is to be understood that this invention is not limited to the particular molecules, compositions, methodologies or protocols described, as these may vary. It is also to be understood that the terminology used in the description is for the purpose of describing the particular versions or embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.
- It must also be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to a “cell” is a reference to one or more cells and equivalents thereof known to those skilled in the art, and so forth. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the present invention, the preferred methods, devices, and materials are now described. AU publications mentioned herein are incorporated by reference. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
- As used herein, the term “about” means plus or minus 10% of the numerical value of the number with which it is being used. For example about 50% means in the range of 45%-55%.
- “Controlled release” or “controlled release formulation” refers to a formulation designed to consistently release a predetermined, therapeutically effective amount of drug or other active agent such as a polypeptide or a synthetic compound below toxic levels over an extended period of time, with the result being a reduction in the number of treatments necessary to achieve the desired therapeutic effect. Preferably the amount of the drug or active agent in the implantable formulations according to embodiments of the present invention establish a therapeutically effective plasma concentration of the drug over a period of 1 month or longer. In the matter of the present invention, a controlled formulation would decrease the number of treatments necessary to achieve the desired effect in terms of decreased estradiol levels or testosterone levels, or an improvement in symptoms associated with central precocious puberty. The controlled release formulations of the present invention achieve a desired pharmacokinetic profile in a subject, preferably commencement of the release of the active agent substantially immediately after placement in a delivery environment, followed by consistent, sustained, preferably zero-order or near zero-order release of the active agent.
- The terms “patient” and “subject” mean all animals including humans. Examples of patients or subjects include humans, cows, dogs, cats, goats, sheep, and pigs.
- The term “pharmaceutically acceptable salts, esters, amides, and prodrugs” as used herein refers to those carboxylate salts, amino acid addition salts, esters, amides, and prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.
- “The term “prodrug” refers to compounds that are rapidly transformed in vivo to yield the parent compounds of the above formula, for example, by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, “Pro-drugs as Novel Delivery Systems,” Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.
- In addition, the compounds of the present invention can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the present invention.
- The term “salts” refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. Representative salts include the acetate, hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate mesylate, glucoheptonate, lactobionate and laurylsulphonate salts, and the like. These may include cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, and the like, as well as non-toxic ammonium, tetramethylammonium, tetraethylammonium, methlyamine, dimethlyamine, trimethlyamine, triethlyamine, ethylamine, and the like. (See, for example, S. M. Barge et al., “Pharmaceutical Salts,” J. Pharm. Sci., 1977, 66:1-19 which is incorporated herein by reference).
- “Treatment” refers to the administration of medicine or the performance of medical procedures with respect to a patient, for either prophylaxis (prevention) or to cure the infirmity or malady in the instance where the patient is afflicted.
- A “therapeutically effective amount” is an amount sufficient to decrease, prevent, or ameliorate the symptoms associated with a medical condition. In the context of hormonal therapy it can also mean to normalize body functions or hormone levels in disease or disorders. For example, a therapeutically effective amount of a controlled release formulation of histrelin is a predetermined amount calculated to achieve the desired effect, e.g., to effectively decrease estradiol levels or testosterone levels in a patient or decrease the symptoms of central precocious puberty.
- In various embodiments, the novel drug delivery device of the invention is designed for implantation into the body of the animal to which the histrelin formulation is to be delivered. The drug delivery devices of the invention are desirably implants containing histrelin in a reservoir, optionally together with another active agent and/or a pharmaceutically acceptable carrier. Such reservoir devices may be composed of hydrophobic or hydrophilic polymers, co-monomers, metals, or other suitable materials. Alternatively, the drug delivery devices may be hydrogels, or other polymeric or co-monomer materials, made up of a matrix having histrelin and any other optional active agents or carriers interspersed throughout. Preferably, the histrelin is dispersed homogeneously throughout the matrix. Yet other suitable implants are known to those of skill in the art and may be readily selected.
- The novel implant drug delivery devices of the invention, in a preferred aspect, are highly useful in the controlled, sustained release of histrelin to animals, e.g., humans, sheep, dogs, cats, turkeys, cattle, etc.
- The amount of histrelin and any other agents employed in the drug delivery devices of the invention will depend not only on the desired daily dose but also on the number of days that dose level is to be maintained. While this amount can be calculated empirically, the actual dose delivered is also a function of any interaction with materials and the carrier, if employed in the device.
- Thus, the drug delivery device may contain a pharmaceutically acceptable carrier which may be in the form of suspending media, solvents, aqueous systems, and solid substrates or matrices. These carriers are known to those of skill in the art and are not intended to be a limitation on the present invention.
- One aspect of the invention is a controlled release pharmaceutical composition comprising histrelin acetate in a controlled release hydrogel device. The composition of the present invention is capable of providing, upon administration to a patient, a release profile of histrelin extending over at least 2 months, preferably at least about 6 months or more. In some embodiments, the histrelin may be released over a period of about 18 months to about 2 years. Preferably histrelin is contained within the hydrogel and the formulation releases a therapeutically effective amount of histrelin over an extended period of time. A therapeutically effective amount is an amount of histrelin, preferably histrelin acetate, that when administered to a patient or subject, ameliorates a symptom of central precocious puberty. In a preferred embodiment, the formulation may further include pharmaceutically acceptable excipients.
- When the compositions of the present invention are administered to a patient, the concentration of histrelin in the patient's plasma over time (release profile) may extend over a period of at least 2 months, preferably about 6 months or more. In a further embodiment, the histrelin may be released over a period of about 18 mouths to about 2 years. The compositions may provide a mean plasma concentration of histrelin of about 0.2 ng/ml to about 2 ng/ml. The compositions may provide a mean plasma concentration at steady state of histrelin in a human patient of from about 0.4 ng/ml to about 0.6 ng/ml. Steady state is the point at which the amount of drug administered over a dosing interval equals the amount of drug being eliminated over that same period.
- The hydrogel is a homogeneous homopolymer or copolymer having a predetermined equilibrium water content (EWC) value formed by the polymerization of a mixture of ethylenically unsaturated monomer A and ethylenically unsaturated monomer B, for example, 2-hydroxyethyl methacrylate (HEMA) and hydroxypropyl methacrylate (HPMA). The predetermined EWC may be calculated by determining the EWC values of the hydrogel homopolymer of hydrophilic monomer A (homopolymer A) and the hydrogel homopolymer of hydrophilic monomer B (homopolymer B); determining the relationship of the EWC values of the homogeneous copolymers AB versus the chemical composition of said copolymer AB; selecting the targeted EWC value and determining the chemical composition of copolymer AB having the targeted EWC value; forming a polymerizable mixture of monomer A and monomer B in amounts sufficient to yield copolymer AB having the targeted EWC value; and effect the polymerization reaction to yield copolymer AB characterized by the targeted EWC value.
- Liquid polymerizable material useful in the hydrophilic products include a wide variety of polymerizable hydrophilic, ethylenically unsaturated compounds, in particular, hydrophilic monomers such as the monoester of an acrylic acid or methacrylic acid with a polyhydroxy compound having an esterifiable hydroxyl group and at least one additional hydroxyl group such as the monoalkylene and polyalkylene polyols of methacrylic acid and acrylic acid, e.g., 2-hydroxyethyl methacrylate and acrylate, diethylene glycol methacrylate and acrylate, propylene glycol methacrylate and acrylate, dipropylene glycol methacrylate and acrylate, glycidyl methacrylate and acrylate, glyceryl methacrylate and acrylate, and the like; the 2-alkenamides, e.g., acrylamide, methacrylamide, and the like; the N-alkyl and N,N-dialkyl substituted acrylamides and methacrylamides such as N-methylmethacrylamide, N,N-dimethylmethacrylamide, and the like; N-vinylpyrrolidone; the alkyl-substituted N-vinylpyrrolidones, e.g., methyl substituted N-vinylpyrrolidone; N-vinylcaprolactam; the alkyl-substituted N-vinyicaprolactam, e.g., N-vinyl-2-methylcaprolactam, N-vinyl-3,5-dimethylcaprolactam, and the like. Acrylic and methacrylic acid can also be useful in these formulations.
- Mixtures of hydrophilic monomers are employed in the polymerization reaction. The type and proportion of monomers are selected to yield a homogeneous polymer, preferably a crosslinked homogeneous polymer, which on hydration possesses the desired EWC value for the contemplated application or use. As shown in
FIG. 1 , this value can be predetermined by preparing a series of copolymers using different monomer ratios, e.g., mixtures of HEMA and HPMA of varying ratios, ascertaining the EWC values of the copolymers, and plotting the relationship of % HPMA (or % HEMA) units in the HPMA/HEMA copolymers vs. weight percent EWC of the copolymers. - In some instances the polymerization of certain hydrophilic monomeric mixtures may result in homogeneous hydrophilic copolymers which dissolve, to a varying extent, in an aqueous medium. In such cases, a small amount, e.g., up to 3 percent, of a copolymerizable polyethylenically unsaturated crosslinking agent can be included in the monomeric mixture to obtain homogeneous crosslinked copolymers which are water-insoluble as well as water-swellable. Slightly crosslinked homopolymer of HEMA has a EWC value of about 38%. Crosslinked copolymers of HEMA and HPMA have EWC values below 38%. On the other hand, crosslinked copolymers of HEMA and acrylamide exhibit EWC values above 38 w/%, e.g., upwards to approximately 75 weight %, and higher. Therefore, depending on the useful or effective elution rate of the active compound. e.g., drug, that is required of a hydrogel delivery system for a particular application, one skilled in the art, by following the teachings disclosed herein, can tailor-make copolymer hydrogel membranes which will elute the drug at the required rate. Preferred copolymers contain about 15 to 70 weight % of HEMA units and from about 85 to 30 weight % of units of a second ethylenic monomer and possess predetermined EWC values in the range of from about 20 to about 75%, preferably 25%. Highly preferred homogenous copolymers are those made from hydrophilic monomeric mixtures containing from about 80 weight % HPMA, and from about 20 weight % HEMA. In further embodiments, the mixture may further contain a small amount of a polyethylenically unsaturated crosslinking agent, e.g., trimethylolpropane trimethacrylate (“TMPTMA”).
- Various aspects of the invention include homogeneous hydrophilic copolymers whose homogeneous polymer structure is formed via the polymerization of a mixture of hydrophilic monomers described previously; and the drug delivery device which utilize the homogeneous polymer cartridges in the delivery system. The polymerization of a mixture of hydrophilic monomers and hydrophobic monomers yields heterogeneous polymers. When hydrophobic segments are present in the polymer, the interfacial free energy increases thus enhancing protein adsorption and mineralization after implantation in an animal. Hydrogels of polyHEMA were measured to have interfacial free energy close to zero. According to the interfacial free energy interpretation, hydrogels of strictly hydrophilic components would strongly appear to be biocompatible with body tissue. Slightly crosslinked polyHEMA is a homogeneous, hydrophilic “homopolymer” (disregarding the relatively small quantities of polymerized crosslinking agent therein) of relatively fixed characteristics or values. Techniques of altering the “homopolymer” polyHEMA to impart to it additional characteristics or properties are difficult, time-consuming, and oftentimes result in erratic property behavior. On the other hand, mixtures of HEMA with varying quantities of other polymerizable hydrophilic comonomer(s) can be polymerized to give predictable homogeneous hydrophilic copolymers having (predetermined) tailor-made properties.
- Useful crosslinking agents which can be included in the polymerizable reaction medium include, for example, the polyethylenically unsaturated compounds having at least two polymerizable ethylenic sites, such as the di-, tri- and tetra-ethylenically unsaturated compounds, in particular, the tri-unsaturated crosslinking agents with/without the di-unsaturated crosslinking compounds, for example, divinylbenzene, ethylene glycol dimethacrylate and diacrylate, propylene glycol dimethacrylate and diacrylate; and the di-, tri- and tetra-acrylate or methacrylate esters of the following polyols: triethanolamine, glycerol, pentaerythritol, 1,1,1-trimethylolpropane; and others.
- The polymerization reaction can be carried out in bulk or with an inert solvent. Suitable solvents include water; organic solvents such as water-soluble lower aliphatic monohydric alcohols as well as polyhydric alcohols, e.g., glycol, glycerine, dioxane, etc.; and mixtures thereof.
- Compounds useful in the catalysis of the polymerizable ethylenically unsaturated compounds include the free-radical compounds and/or initiators of the type commonly used in vinyl polymerization such as the organic peroxides, percarbonates, hydrogen peroxides, and alkali metal sulfates. Illustrative examples include cumene hydroperoxide, t-butyl hydroperoxide, benzoyl peroxide, bis(4-t-butylcyclohexyl) peroxydicarbonate, hydrogen peroxide, 2,4-dichlorobenzoyl peroxide, acetyl peroxide, di-n-propyl peroxydicarbonate, di-t-butyl peroxide, di-sec-butyl peroxydicarbonate, ammonium sulfate, potassium sulfate, and sodium sulfate. A preferred catalyst is one which is effective at moderately low temperature such as at about 20°-80° C., such as tert-butyl peroctoate, benzoyl peroxide, and di(secbutyl) peroxydicarbonate. A conventional redox polymerization catalyst can also be employed. Preferably, polymerization of the ethylenic compounds can be effected using radiation, e.g., U.V., X-Ray, gamma radiation, microwave, or other well-know forms of radiation. A preferred catalyst for U.V. cure is benzoin methyl ether. Catalysts and/or initiators and/or radiation are employed in a catalytically effective amount to optimize the polymerization reaction.
- In a preferred embodiment, small cylindrically shaped implants containing within their core histrelin, preferably histrelin acetate, and optionally, a pharmaceutically acceptable carrier. The membrane thickness (between the interior and exterior surfaces) of the implant is substantially uniform, and serves as a rate-limiting barrier for the release of the contained agent. Such implants can be plasticized or hydrated and reshaped into other geometrically shaped articles for use in various medical applications. The hydrophilic implant as a xerogel, readily absorbs water. In a hydrated state it is referred to as a hydrogel. In either form, it is biocompatible and non-toxic to the host and non-biodegradable. It is, of course, water-swellable and water-insoluble. When the hydrogel attains its maximum level of hydration, the water content of the hydrogel is referred to as “equilibrium water content”. The percent water content of the hydrogel (any state of hydration) is determined as follows:
-
- In the manufacture of the implantable formulation, several factors are considered. The release profile (delay time, release rate, and duration) is determined; the hydrophilic polymeric material is identified; and the diffusivity of the active agent through it (as a rate-limiting membrane) is measured. The hydration profile of the rate-limiting membrane for a given active agent may be readily determined by preparing a film of the selected polymer and subjecting it to a diffusion study, using a two compartment vertical glass cell, as is well known in the art.
- The diffusion coefficient and the water content at which diffusion begins (i.e., below which substantially no diffusion occurs—hereinafter “% Hd”) are determined. A series of membranes is prepared from various polymers. The membranes are then hydrated to their capacity and their equilibrium water contents are measured. The fully hydrated membranes are placed in the two-compartment, vertical glass cells to measure and plot the diffusion of the macromolecular composition through the membrane materials at the various equilibrium water contents. The equilibrium water content of the most hydrated membrane through which no diffusion is detected (i.e., none of the active agent diffuses into the receptor cell) is the % Hd for the system being tested. This can be accomplished by plotting a curve of the permeability vs. equilibrium water content.
- The permeability results (diffusion coefficients) are obtained according to Fick's First Law of Diffusion, by use of the equation:
-
- wherein dQ/dt is the flux through the membrane material (μg/hr); it is measured as the slope of the linear part of the curve of cumulative transport versus time; wherein A is the area of the membrane (cm2); wherein P is the membrane's permeability coefficient (cm2/hr), or DKd, wherein D is the diffusivity of the membrane (cm2/hr), and Kd is the partition coefficient for the membrane/donor solution; wherein 1 is the membrane thickness as measured at the end of the experiment (cm); and wherein Cd is the concentration of the donor solution (μg/cm3).
- The release delay profile is then determined. Another series of polymeric membranes can be prepared, again varying the amounts of crosslinker and monomers. These membranes are then hydrated, but only partially, i.e., to a water content less than or equal to % HL. The partially hydrated membranes are placed in two-compartment vertical glass cells to measure and plot the diffusion of the active compound through the membranes versus time. Buffer solutions for the donor and receptor cells may be selected to contact the partially hydrated membranes and further hydrate them at approximately the same rate at which they will hydrate in the delivery environment. The time between commencement of the diffusion study, i.e., addition of the active agent to the donor cell, and the detection of a pharmaceutically effective concentration of the active agent in the receptor cell is the release delay time for that combination of polymer and initial percent hydration.
- In order to determine the physical dimensions of the cylindrically-shaped device, the total amount of active agent to be delivered must be determined. This is the product of the desired daily dosage and the duration of delivery. In preferred embodiments, the duration of delivery is at least about 2 months, more preferably about 6 months or longer and the desired daily dosage is, for example, about 60 μg to about 70 μg of histrelin.
- The volume of the cylindrical reservoir (core) of a cylindrically-shaped device is equal to Πri 2 h wherein ri is the radius of the reservoir and h is its height. The formula for steady state release from a cylinder is:
-
[dQ/dt]=[2ΠhDKCd C d]/[In(r o /r i)] - wherein ro is the outside radius of the cylindrical device; and wherein Cd is the concentration of drug in the donor solution, i.e., the carrier. Steady state release is obtained when Cd is maintained at saturation. The thickness of the membrane needed for the desired sustained release is, therefore, ro−ri.
- The amount of active agent employed will depend not only on the desired daily dose but also on the number of days that dose level is to be maintained. While this amount can be calculated empirically, the actual dose delivered is also a function of any interaction with materials and the carrier, if employed in the device.
- In various embodiments, the novel formulation of the present invention may contain a pharmaceutically acceptable carrier which may include, but is not limited to, suspending media, solvents, aqueous systems, and solid substrates or matrices.
- Suspending media and solvents useful as the carrier include, for example, oils such as silicone oil (particularly medical grade), corn oil, castor oil, peanut oil and sesame oil; condensation products of castor oil and ethylene oxide; liquid glyceryl trieters of a lower molecular weight fatty acid; lower alkanols; glycols; polyalkylene glycols.
- The aqueous systems include, for example, sterile water, saline, dextrose, dextrose in water or saline, and the like. The presence of electrolytes in the aqueous systems may tend to lower the solubility of the macromolecular drug in them.
- The solid substrates or matrices include, for example, starch, gelatin, sugars (e.g., glucose), natural gums (e.g., acacia, sodium alginate, carboxymethyl cellulose), and the like.
- The carrier may also contain adjuvants such as preserving stabilizing, wetting and emulsifying agents, and the like.
- The hydrating liquid useful in the practice of the invention is typically a liquid simulating the environment in which the active compound will be released, e.g., body fluid, sterile water, tear fluid, physiological saline solution, phosphate buffer solution, and the like. While liquids other than water are useful as the hydrating liquid, the degree to which a hydrophilic membrane is hydrated is referred to as its “water content”.
- By the expressions “copolymer AB” or “copolymer AB consists essentially of monomer A units and monomer B units” is meant that the addition copolymerization of monomer A and monomer B has been effected through the polymerizable ethylenic bond of the said monomers. By way of illustration, if monomer A is 2-hydroxyethyl methacrylate and monomer B is N-methylacrylamide, copolymer AB contains recurring monomer A units and recurring monomer B units.
- Unless the context indicates otherwise, the term “copolymer” includes polymers made by polymerizing a mixture of at least two ethylenically unsaturated monomers.
- By the term “HEMA unit(s)” is meant the structure
- recurring in the polymer obtained by polymerizing hydrophilic material containing 2-hydroxyethyl methacrylate (“HEMA”).
- By the term “HPMA unit(s)” is meant the structure
- obtained by polymerizing hydrophilic material containing hydroxypropyl methacrylate (“HPMA”).
- In one embodiment, a pharmaceutical formulation of the present invention comprises a formulation of histrelin within a mixture of HEMA and HPMA copolymer, preferably about 45% HEMA and 55% HPMA. In preferred embodiments, the pharmaceutical formulation comprises about 25 to about 150 milligrams of histrelin, preferably about 35-45 milligrams of histrelin base. The formulation may further comprise between about 0.5% to about 20% excipients. In a preferred embodiment, the formulation further comprises about 2% stearic acid.
- In one suitable embodiment, hydrogels are suited as Implantable delivery vehicles for use in delivery of histrelin according to the present invention. One hydrogel is prepared by mixing about 60 weight percent to about 95 weight percent comonomers, at least one of which is hydrophilic, and sufficient amounts of a crosslinker and a liquid diffusion enhancer which is miscible with the comonomers, to yield a homogenous copolymer hydrogel having the equilibrium water content (EWC) value in the range from about 20% to about 85%. More preferably, homogenous copolymer hydrogel has a EWC value in the range from about 25% to about 35%. More preferably, another hydrogel is prepared by mixing about 40 weight percent to about 95 weight percent comonomers, at least one of which is hydrophilic, and sufficient amounts of a crosslinker and optionally a liquid diffusion enhancer which is miscible with the comonomers, to yield a homogenous copolymer hydrogel having the equilibrium water content (EWC) value in the range from about 20% to about 85%, more preferably from about 25% to about 35%.
- The polymerizable liquid mixture may also contain about 1 weight percent to about 50 weight percent diffusion enhancer which may be readily selected from among C1-C4 alkyl alcohol, allyl alcohol, tetrahydrofuryl alcohol, cyclohexyl alcohol, diethylene glycol, polyethylene glycols, glycerol, acetone, ethylene glycol monomethyl ether, ethylene glycol monoethyl ether. glyceryl isopropylidene ether dioxane, tetrahydrofuran; ethyl acetate; dimethyl sulfoxide; water, and mixtures thereof. The crosslinker and comonomers may be readily selected by one of skill in the art. Hydrogels and methods of preparation are generally described in International Patent Application Number PC/US00/01664, filed Jan. 26, 2000 for “Hydrogel Compositions Useful for the Sustained Release of Macromolecules and Methods of Making Same.” Other suitable hydrogels may be readily selected by one of skill in the art. See, e.g., U.S. Pat. Nos. 5,266,325; 4,959,217; and 5,292,515.
- Another particularly desirable hydrogel is prepared by mixing about 40 weight percent to about 95 weight percent comonomers, at least one of which is hydrophilic, and sufficient amounts of a crosslinker and optionally a liquid diffusion enhancer which is miscible with the comonomers, to yield a homogenous copolymer hydrogel having the equilibrium water content (EWC) value in the range from about 20% to about 85%. More preferably, homogenous copolymer hydrogel has a EWC value in the range from about 25% to about 35%.
- In one embodiment, the hydrogel comprises 2-hydroxyethyl methacrylate (HEMA) and hydroxypropyl methacrylate (HPMA). The hydrogel may also further comprise a crosslinking agent, such as, for example (TMPTMA). In a preferred embodiment, the hydrogel comprises about 45% of HEMA, about 54.5% HPMA and about 0.5% TMPTMA.
- In a further embodiment, a delivery device capable of providing a sustained release of a therapeutically effective amount of GnRH agonist is provided. Preferably the controlled release is achieved of a period of time of at least 6 months or more, more preferably about 1 to about 2 years. In a preferred embodiment, the delivery device comprises a hydrogel, wherein the composition of the hydrogel is based upon the desired daily dose and release profile. In a preferred embodiment, a delivery device capable of providing controlled release of about 60 μg to about 70 μg of histrelin per day is provided. In a more preferred embodiment, the delivery device provides about 65 μg of histrelin per day.
- While not bound by theory, the diffusion of the drug occurs through water channels in the hydrogel. Controlling the water content of the hydrogel allows for manipulation of the release profile of the agent within the hydrogel. The release may also be manipulated by the geometry of the drug delivery device, including, for example, the area, wall thickness and diameter. Treatment of particular diseases or conditions may require higher or lower therapeutic levels or differing release profiles, which may be achieved through the design of the drug delivery device of the present invention.
- The hydrating liquid useful in the hydrogels used in the invention is typically a liquid simulating the environment in which the active compound will be released, e.g., body fluid, sterile water, tear fluid, physiological saline solution, phosphate buffer solution, and the like. While liquids other than water are useful as the hydrating liquid, the degree to which a hydrophilic membrane is hydrated is referred to as its “water content.”
- In another suitable embodiment, the implant may be in the form of an osmotic pump, such as described by Alza (see, e.g., U.S. Pat. Nos. 4,285,987 and 5,273,752) or Merck (see, e.g., European Patent No. 314,206), among others. In another example, the implant device may be composed of a hydrophobic membrane material, such as ethylmethacrylate (EMA) and ethylenevinylacetate (EVA). Other suitable implant delivery devices include bioresorbable polymer systems (see, e.g., International Patent Application No. WO98/44964, Bioxid and Cellomeda, U.S. Pat. Nos. 5,756,127 and 5,854,382). Suitable bioresorbable implant devices have been described in the literature and may be composed of, for example, polyesters, polyanhydrides, or lactic acid/glycolic acid copolymers (see, e.g., U.S. Pat. No. 5,817,343 Alkermes Inc.).
- Regardless of whether the delivery device is composed of a hydrogel, EVA/EMA polymer, bioresorbable material, metal or other material, the devices useful in the invention(s) provide sustained release of histrelin over extended periods of time. This time period may range from a month to a year or several years, depending on the desired administration regimen. Preferably, histrelin will be released in daily doses over a period of about 2 months or longer, and preferably over a period of about six months to one year or longer. In some embodiments, the histrelin may be released over a period of about 18 months to about 2 years. It is to be understood that this time factor is a variable depending on the rate-releasing membrane of choice, its interconnecting pore structure, the solubility of the active compound(s) in the liquid medium, and other considerations well known to those skilled in the art.
- Where the delivery device is composed of a hydrogel, it may be prepared such that the hydrogel forms the walls of a cavity which contain the active agent. A predetermined amount of histrelin per se or an admixture with an inert, non-toxic material or as a suspension in a non-toxic material or as a suspension in a non-toxic medium, e.g., medical grade silicone oil, is introduced into the cavity to partially fill the core. The void in the core is thereafter sealed to prevent leakage into or out of the vesicle. Preferably this can be accomplished by introducing sufficient polymerizable material into the void to cover the layer of inert material or to substantially or completely fill the void and thereafter effecting a polymerization reaction to form a plug of water-swellable, water-insoluble polymer which seals the opening of the vesicle. The hydrophilic polymer plug, upon maximum hydration, will have an equilibrium water content value of the hydrophilic vesicle. Using polymerizable material comprising ethylenically unsaturated monomer(s) and desirably crosslinking agent(s), a polymer plug grafted to the inner surface of the vesicle can be obtained.
- In a currently desired embodiment, hydrophilic cartridges are prepared by the rotational casting of polymerizable material in a tubular mold, as described in U.S. Pat. Nos. 5,266,325 and 5,292,515, which are incorporated herein by reference.
- Briefly, the internal radius of the tube is approximately 1.2 to 1.3 mm, and may be larger. The tube is rotated about its longitudinal axis which is maintained parallel to the ground. Rotational speeds are of the order of 2150 rpm, though greater or lesser speeds could be used, e. g., 1000 rpm or less to 3000 rpm and more. The tubes are fabricated of polyethylene, polypropylene, glass, or other suitable materials. When the polymerizable mixture within the spinning tube stabilizes to the predetermined shape, U.V. light at a distance of less than one foot is then directed at the spinning tube for several minutes, e.g., about 7 minutes, to polymerize the mixture to the shaped product. The shaped product is cured and annealed as follows: Thermal Cure: 60 minutes at 65° C.; Postcure: 30 minutes at 95° C.; Annealing: 30 minutes at 115° C. with gradual cooling to about 25° C.
- After shaping and polishing the closed end of the cartridge to an oval-like cylindrical profile, there is obtained small cylindrically-shaped objects having smooth, unscored cylindrical surfaces. The cartridge may be of any desired combination of dimensions. For example, the internal radius may be about 0.98 mm; the external radius may be about 1.3 mm; and the length may be about 25 mm, or of larger or smaller dimensions, as desired.
- Smooth, unscored cylindrically-shaped objects of various lengths, e.g., up to 25 cm and longer, can also be prepared in accordance with the teachings herein.
- Such objects, in a hydrated state or plasticized with a non-toxic biocompatible material, can be formed into desired shapes. A ring shape, for use as pessaries, surgical implants, etc. Yet other drug delivery devices and implant shapes may be prepared using techniques known to those of skill in the art or purchased from commercial sources.
- In preferred embodiments, upon hydration the length of the implantable delivery device is about 32-37 mm, the outside diameter is about 3-3.5 mm, the cartridge walls are about 0.5 mm and the cavity diameter is about 2-2.5 mm.
- In a further embodiment, the invention provides for a method of delivering histrelin, alone or in combination with other active agents, upon implantation in a patient. The hydrogel delivery device of the present invention is hydrated with a hydrating liquid prior to implantation in the patient, so as to provide release of histrelin upon implantation.
- In another embodiment, a method of inhibiting release of histrelin prior to implantation is provided. The hydrogel implant delivery device of the present invention is stored in a hydrating liquid prior to implantation in the patient, so as to limit release of histrelin from the implant prior to implantation. In preferred embodiments, the hydrating liquid is sodium chloride solution.
- The invention provides a method of delivering histrelin, alone or in combination with other active agents, to a veterinary or human patient in need thereof. Typically, such a patient has a disease or condition such as central precocious puberty.
- In order to treat a patient, one or more delivery devices as described herein can be implanted subcutaneously in an animal by perforation. Such devices are characterized by a length of 10 to 50 mm, or less (e.g., 6 to 9 mm), an external diameter of 2 to 5 mm, or less (e.g., 1.5 to 1.9 mm). The dimensions of the device (e.g., a cartridge) can vary outside of the limits stated above depending, in particular, on the medical application involved. Animals such as sheep, cows, goats, cattle, and large animals, in general, can tolerate implantation by perforation of larger dimensional drug delivery devices. Implantation can be effected by other means, e.g., open surgery.
- In one embodiment, the drug delivery device is a biodegradable matrix, which is bioresorbed and eliminated from the body following completion of the course of therapy, e.g., at least about 2 months, or more preferably about 12 months or longer. Alternatively, a selected delivery device may be removed by surgical means.
- A method of treating a disease associated with a hormonal disorder is also provided. The method may include administering histrelin and maintaining a plasma concentration of histrelin of about 0.2 ng/ml to about 2 ng/ml and maintaining a plasma concentration of histrelin at steady state between about 0.4 ng/ml and about 0.6 ng/ml over an extended period of time, preferably at least about 2 months, and more preferably about 6 months or longer. Such hormonal disorders include CPP or the like. In one embodiment, the method may comprise administering one or more delivery devices comprising a hydrogel of about 45% of HEMA, about 54.5% HPMA, about 0.5% TMPTMA and histrelin acetate.
- One embodiment is a method of decreasing estradiol levels or testosterone levels by administering histrelin and maintaining a steady state plasma concentration of histrelin between about 0.4 ng/ml and about 0.6 ng/ml, over an extended period of time, preferably at least about 2 months, and more preferably about 6 months or longer. Another embodiment is a method of decreasing symptoms of CPP by administering histrelin and maintaining a plasma concentration of histrelin between about 02 ng/ml to about 2 ng/ml over an extended period of time, preferably at least about 2 months, and more preferably about 6 months or longer.
- Another embodiment is a method of treating CPP comprising administering at least one hydrogel implant of the present invention, or two or more hydrogel implants of the present invention. In the method, each hydrogel of the two hydrogel implants administered may contain between about 25 to about 150 milligrams of histrelin acetate, preferably about 40 to about 90 milligrams of histrelin acetate, more preferably about 50 milligrams of histrelin acetate and release a therapeutically effective amount of histrelin over a period of at least two months, preferably six months or longer.
- In a further embodiment, a method of treating CPP comprises administering one or more implants comprising a hydrogel and histrelin. Preferably, the hydrogel implants contain about 50 milligrams of histrelin acetate and release from about 60 μg to about 70 μg of histrelin acetate substantially upon implantation for a period of at least 2 months, more preferable for about 1 year.
- Another aspect is a therapeutic composition of a hydrogel and histrelin, wherein, upon implantation, histrelin is released at a rate that provides and/or maintains a Css of about 0.2 ng/ml to about 2 ng/mi. A further embodiment is a therapeutic composition of a hydrogel and histrelin, wherein, upon implantation, the histrelin is released at an average rate of from about 60 to about 70 μg/day, preferably an average of about 65 μg daily over an extended period of time, preferably at least about two months, more preferably about six months or longer.
- Another embodiment is a controlled release formulation comprising histrelin and a hydrophilic polymer, which permits release of the histrelin at a rate of about 60 μg to about 70 μg per day over about six months or longer in vitro. In a further embodiment, the hydrophilic polymer of the formulation permits release of histrelin at an average rate of about 65 μg per day in vitro.
- In a further embodiment, a controlled release formulation comprising histrelin and a hydrophilic polymer is provided that releases from about 140 μg to about 40 μg per day over about six months or longer, more preferably about 135 μg to about 60 μg per day over about six months or longer.
- The amount of a pharmaceutically acceptable histrelin, salt, solvated, or prodrug thereof included in the pharmaceutical composition of the present invention will vary, depending upon a variety of factors, including, for example, the specific histrelin used, the desired dosage level, the type and amount of hydrogel used, and the presence, types and amounts of additional materials included in the composition. The amount of histrelin, or a derivative thereof in the formulation varies depending on the desired dose for efficient drug delivery, the molecular weight, and the activity of the compound. The actual amount of the used drug can depend on the patient's age, weight, sex, medical condition, disease or any other medical criteria. The actual drug amount is determined according to intended medical use by techniques known in the art. The pharmaceutical dosage formulated according to the invention may be administered about once every six months as determined by the attending physician.
- Typically, the histrelin is formulated in the implant or other pharmaceutical composition in amounts of about 25 milligrams to about 150 milligrams, preferably about 40 to about 90 milligrams of histrelin. Preferably, the amount of histrelin in the composition is formulated to release from about 60 μg to about 70 μg of histrelin daily and maintain therapeutic levels in the patient's blood at about 0.2 ng/ml to about 2 ng/ml over an extended period of time.
- The hydrogel device in which histrelin is contained provides a controlled release of histrelin into the plasma of the patient. Hydrogels suitable for controlling the release rate of histrelin for use in the pharmaceutical compositions of the present invention include polymers of hydrophilic monomers, including, but not limited to HPMA, HEMA and the like. Such hydrogels are also capable of preventing degradation and loss of histrelin from the composition.
- In one embodiment, a pharmaceutical formulation of the present invention comprises histrelin acetate contained within a hydrophilic copolymer of 2-hydroxyethyl methacrylate and hydroxypropyl methacrylate. In a preferred embodiment, the copolymer of the pharmaceutical formulation comprises about 45% HEMA and about 55% HPMA. In another preferred embodiment, the formulation further comprises stearic acid.
- The amount of the hydrogel included in the pharmaceutical composition of the present invention will vary depending upon a variety of factors, including, for example, the specific matrix used, its molecular weight, its hydrophilicity, the type and amount of histrelin used, and the presence, types and amounts of additional materials included in the composition.
- The size, shape and surface area of the implant may also be modified to increase or decrease the release rate of histrelin from the implant.
- The formulations of the present invention exhibit a specific, desired release profile which maximizes the therapeutic effect while minimizing adverse side effects. The desired release profile may be described in terms of the maximum plasma concentration of the drug or active agent (Cmax) and the plasma concentration of the drug or active agent at steady state (Css).
- Suitably, treatment of CPP or related conditions using the drug delivery devices of the invention may be readily combined with other therapies administered by routes other than through the use of an implantable devices. For example, treatment with histrelin according to the invention may be combined with other treatments or therapies.
- The following examples are provided to illustrate the invention and do not limit the scope thereof. One skilled in the art will appreciate that although specific reagents and conditions are outlined in the following examples, modifications can be made which are meant to be encompassed by the spirit and scope of the invention.
- Hydrogel implants were prepared in accordance with the present invention. In particular, about 45% HEMA, 54.5% HPMA and about 0.5% TMPTMA were admixed with 0.3% benzoinmethylether (BME) and 0.1% percadox-16.
- Ten histrelin implants were prepared in accordance with the present invention. In particular, the histrelin implants comprised about 45% HEMA and about 55% HPMA. The resulting hydrogel implants exhibited an equilibrium water content (EWC) of about 29%. The implants were prehydrated. The release rates were measured over sixty weeks. The release profile for the histrelin implants is provided in
FIG. 2 . - This was an open-label study in which children with CPP were assigned to receive one or two histrelin hydrogel implants, containing 50 mg of histrelin each, depending on their body weight and the ease of insertion of the implant, as determined on a case-by-case basis by the principal investigator and the surgeon performing the insertion. The histrelin implants were supplied in about 2.0 mL of 1.8% sodium chloride solution. Following the first 9 months of the study, the children were assigned to one of two tracks. Children in the first track had their implant(s) removed, and one new implant inserted. The implant remained in place in those in the second track. The children in both tracks continued in the study for an additional 9 months. In total, eleven
girls ages 3 to 11 years old were enrolled in this study. Ten of the 11 patients completed at least 12 months of treatment. - Study visits occurred at baseline, 4 weeks (Month 1), 3 months, and then every 3 months for the remainder of the study. Blood samples for determination of histrelin serum concentrations and determination of hormone levels were collected at each clinic visit. GnRH challenge tests were performed with Relefact® LHRH 0.1 mg (=100 μg gonadorelin) intravenous injection before the implant insertion, at
month 9, and at month 18 for all patients. GnRH challenge tests were also performed at every visit aftermonth 9 for the patients whose implant(s) remained in place after that time. If at any visit there was incomplete hormonal suppression or if the clinical evaluation indicated disease progression, the implant was to be removed and the child offered a new implant. - All 11 patients were being treated with the GnRH analogs when they entered the study. The duration of treatment at study entry ranged from less than 2 weeks to 39 months. Eight of the patients had been treated for 7 months or less, one for 18 months, one for 21 months, and one for 39 months. The standard treatments were decapeptyl embonate (9 patients), diphereline (1 patient), or both decapeptyl and diphereline (1 patient). These were administered as intramuscular depot injections every 21 to 28 days. The histrelin implant was inserted anywhere from 2 days to 1.5 months after the last depot injection.
- Five patients were treated with two implants, and a single implant was inserted in the remaining six patients. One of the patients with two implants had one removed at the time of suture removal; in analyses of data by number of implants, she is included in the group with one implant. At
month 9, five patients had their implants removed and had a single new implant inserted. The remaining six patients had their original implant(s) left in place for 18 months. - The standard GnRH treatment had suppressed estradiol levels to below 73 pmol/L in 10 of the 11 patients at the time of implant insertion. None of these 10 patients bad an estradiol level greater than 73 pmol/L at any evaluation through
month 12, i.e., their values remained within the prepubertal range. - Basal luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels were suppressed due to standard GnRH treatment at baseline and remained suppressed following implant insertion. Suppression of peak LH and FSH responses to GnRH testing was maintained for 9 months following implant insertion in all 11 girls, and for 12 months in the six girls who had their original implants left in place and had GnRH challenge testing at 12 months.
- The results of the first 12 months of the study, described below, support the safety and efficacy of the histrelin implant in patients with CPP. This data also suggest that one implant is as effective as two implants in the suppression of estradiol, LH and FSH. Treatment with the histrelin implant maintained suppression of estradiol and basal LH and FSH initiated by treatment with standard GnRH analogs.
- Estradiol Levels. Table 1 displays the mean values, and mean changes from baseline, in estradiol levels for the ITT population during 9 months of treatment. The mean values changed little over time, suggesting that the suppression achieved with standard treatment for CPP was maintained during treatment with the histrelin implant.
-
TABLE 1 Mean Values and Mean Changes in Estradiol (pmol/L) Through Month 9 (ITT Population) All ITT Patients (N = 11) Visit (Month) N Mean (SD) Mean Change (SD) Baseline (Visit 1/Day 1) 11 36.07 (23.462) Visit 2 (Mouth 1) 11 35.70 (19.348) −0.37 (26.839) Visit 3 (Month 3) 11 37.64 (18.424) 1.56 (12.008) Visit 4 (Month 6) 11 32.56 (22.192) −3.51 (15.429) Visit 5 (Month 9) 11 26.38 (19.684) −9.69 (25.012) - Table 2 displays the estradiol results for subsets of the patients categorized by the member of implants they received. The suppression of estradiol levels was maintained regardless of whether the patients received one or two implants. Within the group of patients who received one implant, the results were similar regardless of baseline weight.
-
TABLE 2 Mean Values and Mean Changes in Estradiol (pmol/L) Through Month 9 by Number of Implants (ITT Population)N Mean (SD) Mean Change (SD) 1 Implant Baseline (Visit 1/Day 1) 7 34.07 (17.68) Visit 2 (Month 1) 7 36.47 (22.378) 2.40 (23.574) Visit 3 (Month 3) 7 32.39 (12.510) −1.69 (11.688) Visit 4 (Month 6) 7 25.33 (11.523) −8.74 (12.420) Visit 5 (Month 9) 7 25.56 (17.950) −11.51 (29.223) 2 Implants Baseline (Visit 1/Day 1) 4 39.58 (34.41) Visit 2 (Month 1) 4 34.35 (15.570) −5.23 (35.216) Visit 3 (Month 3) 4 46.83 (25.329) 7.25 (11.818) Visit 4 (Month 6) 4 45.23 (32.252) 5.65 (17.586) Visit 5 (Month 9) 4 33.08 (23.520) −6.50 (18.867) - Table 3 summarizes the estradiol results after 9 months. Suppression of estradiol levels appeared to be maintained in patients who received new implants at 9 months and also in patients whose original implant(s) remained in place at 9 through 12 months.
-
TABLE 3 Mean Values and Mean Changes in Estradiol (pmol/L) After 9 Months of Treatment by Track (ITT Population) Mean Change (SD) N Mean (SD) from Baseline First Track (New Implant) Visit 5 (Month 9) 5 31.48 (23.691) −6.68 (24.968) Visit 6 (Month 12) 4 12.70 (5.560) −12.93 (10.984) Second Track (1 Implant) Left in Place) Visit 5 (Month 9) 5 22.90 (18.530) −12.20 (30.329) Visit 6 (Month 12) 5 23.56 (16.475) −11.54 (5.038) Second Track (2 Implants Left in Place) Visit 5 (Month 9) 1 18.30 −12.20 Visit 6 (Month 12) 1 25.80 −4.70 - LH and FSH Levels. Basal gonadotropin levels were suppressed at baseline and remained suppressed following implant insertion. The mean values showed little change during the first 9 months of the study, as shown in Table 4.
-
TABLE 4 Mean Values and Mean changes in LH and FSH (mIU/mL) Through Month 9 (ITT Population All ITT Patients (N = 11) N Mean (SD) Mean Change (SD) LH (mIU/mL) Baseline (Visit 1/Day 1) 11 0.47 (0.358) Visit 2 (Month 1) 11 0.26 (0.163) −0.21 (0.425) Visit 3 (Month 3) 11 0.25 (0.199) −0.22 (0.444) Visit 4 (Month 6) 11 0.20 (0.144) −0.28 (0.416) Visit 5 (Month 9) 11 0.20 (0.121) −0.28 (0.409) FSH (mIU/mL) Baseline (Visit 1/Day 1) 11 1.20 (0.429) Visit 2 (Month 1) 11 1.07 (0.531) −0.13 (0.445) Visit 3 (Month 3) 11 1.11 (0.602) −0.09 (0.499) Visit 4 (Month 6) 11 1.08 (0.517) −0.12 (0.438) Visit 5 (Month 9) 11 1.07 (0.535) −0.13 (0.427) - Table 5 shows the mean values and mean changes in LH and FSH for patients categorized the by the number of implants. The mean changes in LH were larger for patients with two implants than for those with one implant. The subgroup of patients with one implant showed a mean decrease in FSH during the first month of treatment. This decrease was maintained through
month 9. The subgroup of patients with two implants showed a small mean increase in FSH during the first 9 months of treatment. - The pattern of changes in LH was similar regardless of baseline weight in the subgroup of patients with one implant. The patients who weighed >40 kg at baseline had larger mean decreases in FSH at every evaluation (ranging from −0.37 to −0.50 mIU/mL) than did those who weighed 540 kg at baseline (ranging from −0.13 to −0.25 mIU/mL).
-
TABLE 5 Mean Values and Mean Changes in LH and FSH (mIU/mL) Through Month 9 by Number of Implants (ITT Population) N Mean (SD) Mean Change (SD) LH (mIU/mL) 1 Implant Baseline (Visit 1/Day 1) 7 0.39 (0.107) Visit 2 (Month 1) 7 0.31 (0.177) −0.07 (0.198) Visit 3 (Month 3) 7 0.31 (0.227) −0.07 (0.229) Visit 4 (Month 6) 7 0.23 (0.170) −0.16 (0.199) Visit 5 (Month 9 7 0.24 (0.127) −0.14 (0.172) 2 Implants Baseline (Visit 1/Day 1) 4 0.63 (0.597) Visit 2 (Month 1) 4 0.18 (0.096) −0.45 (0.635) Visit 3 (Month 3) 4 0.14 (0.068) −0.48 (0.639) Visit 4 (Month 6) 4 0.14 (0.068) −0.48 (0.639) Visit 5 (Month 9) 4 0.12 (0.057) −0.51 (0.620) FSH (mIU/mL) 1 Implant Baseline (Visit 1/Day 1) 7 1.19 (0.426) Visit 2 (Month 1) 7 0.93 (0.325) −0.26 (0.346) Visit 3 (Month 3) 7 0.90 (0.280) −0.29 (0.353) Visit 4 (Moilth 6) 7 0.87 (0.287) −0.31 (0.363) Visit 5 (Month 9) 7 0.89 (0.372) −0.30 (0.420) 2 Implants Baseline (Visit 1/Day 1) 4 1.23 (0.499) Visit 2 (Month 1) 4 1.33 (0.772) 0.10 (0.560) Visit 3 (Month 3) 4 1.48 (0.873) 0.25 (0.580) Visit 4 (Month 6) 4 1.45 (0.666) 0.23 (0.359) Visit 5 (Month 9) 4 1.40 (0.673) 0.18 (0.250) - Table 6 summarizes the LH and FSH results after 9 months of treatment. Suppression of LH and FSH levels was maintained in patients who received new implants at 9 months and also in patients whose original implant(s) remained in place at 9 and 12 months.
-
TABLE 6 Mean Values and Mean Changes in LH and FSH (mIU/mL) After 9 Months of Treatment by Track (ITT Population) Mean Change (SD) N Mean (SD) from Baseline LH (mIU/mL) First Track (New Implant) Visit 5 (Month 9) 5 0.23 (0.174) −0.39 (0.602) Visit 6 (Month 12) 4 0.28 (0.171) −0.13 (0.171) Second Track (1 Implant Left in Place) Visit 5 (Month 9) 5 0.18 (0.045) −0.20 (0.158) Visit 6 (Month 12) 5 0.22 (0.045) −0.16 (0.167) Second Track (2 Implants Left in Place) Visit 5 (Month 9) 1 0.10 −0.10 Visit 6 (Month 12) 1 0.10 −0.10 FSH (mIU/mL) First Track (New Implant) Visit 5 (Month 9) 5 1.42 (0.502) 0.02 (0.589) Visit 6 (Month 12) 4 1.25 (0.635) −0.13 (0.772) Second Track (1 Implant Left in Place) Visit 5 (Month 9) 5 0.86 (0.378) −0.28 (0.228) Visit 6 (Month 12) 5 1.04 (0.483) −0.10 (0.447) Second Truck (2 implants Left in Place) Visit 5 (Month 9) 1 0.40 −0.10 Visit 6 (Month 12) 1 0.40 −0.10 - Results of GnRH Challenge Test.
- The results of the GnRH challenge tests are summarized in Table 7 for the ITT population. At baseline, there were mean increases in LH and
FSH 20 minutes after administration of LHRH. The mean value for LH decreased at 40 and 60 minutes, whereas the value for FSH remained elevated. During treatment with the histrelin implant, there was no mean increase in LH or FSH in response to administration of LHRH. -
TABLE 7 Summary of GnRH Challenge Test Results (ITT Population) Mean N 0 Min 20 Min 40 Min 60 Min LH (mIU/mL) Baseline (Visit 1/Day 1) 11 0.47 1.30 1.15 0.91 Visit 3 (Month 3) 5 0.22 0.22 0.28 0.22 Visit 4 (Month 6) 10 0.16 0.18 0.19 0.15 Visit 5 (Month 9) 11 0.20 0.24 0.22 0.22 FSH (mIU/mL) Baseline (Visit 1/Day 1) 11 1.20 1.66 1.62 1.63 Visit 3 (Month 3) 5 0.92 0.94 0.96 0.92 Visit 4 (Month 6) 10 1.11 1.10 1.09 1.11 Visit 5 (Month 9) 11 1.07 1.11 1.11 1.09 - The results were similar for the subsets of patients who had one or two implants and for the patients with one implant categorized by baseline weight.
- GnRH challenge tests were done at
month 12 only for patients whose implants were left in place at month 9 (second track). Atmonth 12, these patients continued to show no mean increase in LH and FSH levels in response to administration of LHRH. - These results suggest that standard GnRH analog treatment had resulted in markedly suppressed gonadotropin response to GnRH stimulation before the patients received the histrelin implants. Complete suppression of peak LH and GnRH to GnRH testing was maintained for 9 months following implant insertion in all 11 girls and for 12 months in those whose implants were left in place.
- IGF Levels.
- The mean value for IGF-1 was 350.18 ng/mL at baseline and 311.82 ng/mL at
month 9, yielding a mean change of −38.36 ng/mL. The mean value for IGF-BP3 was 5.47 mg/L at baseline and 6.51 mg/L atMonth 9, yielding a mean change of 1.04 mg/L. - No patient showed a shift from baseline to
Month 9 in IGF-1 levels. Ten (91%) of the patients had values within the normal range at both evaluations, and the remaining one (9%) patient had values above the normal range at both evaluations. - Seven (64%) patients had IGF-BP3 values at baseline that were above the normal range for their age and sex. One of these patients had a value within the normal range at
Month 9, whereas the remaining six patients had values that remained above normal. Four (36%) patients had normal IGF-BP3 values at baseline. One of these patients had a value within the normal range atMonth 9. The remaining three patients, identified below, had shifts from within the normal range at baseline to above the normal range atmonth 9. -
- Patient 104 (3 years old), whose value increased from 2.7 mg/L at baseline to 5.3 mg/L at month 9 (normal range, 0.8 to 3.8 mg/L)
- Patient 107 (8 years old), whose values increased from 4.7 mg/L at baseline to 5.9 mg/L at month 9 (normal range, 1.2 to 4.7 mg/L)
- Patient 110 (8 years old), whose value increased from 4.2 mg/L at baseline to 5.9 mg/L at month 9 (normal ranges, 1.2 to 4.7 mg/L at baseline and 1.6 to 4.0 mg/L at month 9)
- Bone Age by X-Ray.
- Determination of each patient's bone age by x-ray was performed at screening and again at
month 9. At screening, the mean bone age was 10.10 years (range, 4.5 to 12.75 years) whereas the mean chronologic age was 8.4 years (range, 3.58 to 11.00 years). Thus, bone age was advanced compared to the chronological age in all girls at the time of implant insertion. The bone age increased by a mean of 0.35 years, to 10.46 years, atmonth 9. The increase in chronologic age atmonth 9 was 0.96 years. Therefore, there was no advancement in bone age during treatment with the histrelin implant and, in fact, the bone age advancement regressed during treatment. - Histrelin Levels.
-
FIG. 3A displays the serum histrelin concentrations for each patient with 1 implant (track 1) at all evaluation times andFIG. 3B displays the serum histrelin concentrations for each patient with 2 implants (track 2) at all evaluation times. Histrelin levels remained fairly constant over time for most patients. - Physical Findings.
- Temperature, blood pressure, heart rate, weight, and height were measured at every evaluation. The mean changes that occurred in temperature, blood pressure, and heart rate were small, showed no time-related trends, and were not clinically meaningful.
- It is difficult to interpret the mean values for height and weight for the patients in this population whose age range (3 to 11 years) covers times of different rates of growth in children. Therefore, height, weight, and BMI data for each patient at baseline and
month 12 were transformed to Z-scores based on the patients' age in months and sex (data not shown) Most of the patients had values for all Z-scores that were between −1.96 (5th percentile) and 1.96 (95th percentile). The following patients had values that were outside that range; - Height adjusted for age: Patients 105 (2.02 at baseline and 1.58 at month 12); Patient 107 (2.48 at baseline and 2.18 at month 12); and Patient 111 (1.98 at baseline and 2.16 at month 12).
- Weight adjusted for age: Patient 103 (1.98 at baseline and 1.98 at month 12); Patient 107 (2.41 at baseline and 2.45 at month 12); and Patient 111 (2.10 at baseline and 2.32 at month 12).
- BMI adjusted for age: Patient 102 (−2.49 at baseline to −1.25 at month 12); Patient 103 (2.04 at baseline and 1.95 at month 12); and Patient 107 (1.88 at baseline and 2.04 at month 12).
- Thus, most of these patients had Z-scores that were either above the 95th percentile or below the 5th percentile at both baseline and
month 12, or had values above the 95th at baseline which decreased to below the 95 percentile bymonth 12. The only patient with an increase from below the 95th percentile at baseline to above the 95th percentile atmonth 12 was Patient 107, for BMI only. - The height velocity at insertion and at nine months following implantation were measured.
FIG. 5 illustrates the decrease of height velocity during treatment. Similarly, the bone age to chronologic age ratio was assessed at insertion and at nine months following implantation, as illustrated inFIG. 6 . - Tanner Stage. The Tanner Stage is a subjective evaluation of sexual maturation. For the girls enrolled in this study, pubertal stages of breasts and pubic hair were rated on a scale of 1 to 5, where 5 represented the most advanced level of sexual maturation.
- Shift tables displaying changes in Tanner Stage from screening to each subsequent visit are presented in
FIG. 4 . At screening, two (18%) patients were ratedTanner Stage 2, five (45%) were ratedTanner Stage 3, and four (36%) were ratedTanner Stage 4 for breasts. All of theStage 4 patients were ratedStage 3 at every evaluation frommonth 3 onward. OneStage 3 patient was ratedStage 2 at every evaluation frommonth 2 onward. FourStage 3 patients were ratedStage 3 at all evaluations frommonth 2 tomonth 9. Atmonth 12, three of those patients were ratedStage 3 whereas the fourth patient (Patient 101) was ratedStage 4. The latter patient was the only patient who had an increase in Tanner Stage for breast at any time during the study. - At screening, two (18%) patients were rated
Tanner Stage 1, five (45%) were ratedStage 2, three (27%) were ratedStage 3, and one (9%) was ratedStage 4 for pubic hair. Theonly Stage 4 patient was ratedStage 3 at every evaluation frommonth 1 onward. Of the remaining patients, few had increases in Tanner Stage: one fromStage 1 to 2, two fromStage 2 to 3, and one fromStage 3 to 4. - The results show that the histrelin implant maintains suppression of gonadotropins and estradiol for at least 12 months in girls with CPP. Skeletal maturation was significantly advanced at the time of implant insertion, but progressed more slowly during treatment.
- There were no deaths or other serious adverse events during the first 12 months of treatment. One patient failed to complete 12 months of treatment because of an adverse event.
Patient 103 was a 10-year-old girl who received two implants. She developed a local infection at the implant site, which resolved in 10 days after treatment with oral antibiotics. AtMonth 9, she was assigned to the first track and had her two original implants removed. A new implant was inserted in the same incision. A wound infection developed approximately 1 week after the new implant had been inserted. This infection also resolved after treatment with oral antibiotics. Ten days after insertion of the new implant, it was found to be partially extruded from the incision site and was removed. The patient withdrew from the study after the implant was removed. Seven (64%) patients experienced at least one adverse event during the study. The most commonly reported events were conditions related to the implant site and infections. All of the events were rated mild by the investigator. - What has been described and illustrated herein are embodiments of the invention along with some of their variations. The terms, descriptions and figures used. herein are set forth by way of illustration only and are not meant as limitations. Those skilled in the art will recognize that many variations are possible within the spirit and scope of the invention, which is intended to be defined by the following claims and their equivalents in which all terms are meant in their broadest reasonable sense unless otherwise indicated.
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/793,391 US20200179480A1 (en) | 2004-06-17 | 2020-02-18 | Compositions and methods for treating precocious puberty |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58052004P | 2004-06-17 | 2004-06-17 | |
US11/155,822 US8062652B2 (en) | 2004-06-17 | 2005-06-17 | Compositions and methods for treating precocious puberty |
US13/291,764 US20120114730A1 (en) | 2004-06-17 | 2011-11-08 | Compositions and methods for treating precocious puberty |
US14/456,602 US20140349936A1 (en) | 2004-06-17 | 2014-08-11 | Compositions and methods for treating precocious puberty |
US14/935,943 US20160193280A1 (en) | 2004-06-17 | 2015-11-09 | Compositions and methods for treating precocious puberty |
US15/407,632 US20170119843A1 (en) | 2004-06-17 | 2017-01-17 | Compositions and methods for treating precocious puberty |
US16/002,578 US20180280467A1 (en) | 2004-06-17 | 2018-06-07 | Compositions and methods for treating precocious puberty |
US16/793,391 US20200179480A1 (en) | 2004-06-17 | 2020-02-18 | Compositions and methods for treating precocious puberty |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/002,578 Continuation US20180280467A1 (en) | 2004-06-17 | 2018-06-07 | Compositions and methods for treating precocious puberty |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200179480A1 true US20200179480A1 (en) | 2020-06-11 |
Family
ID=34982411
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/155,822 Active 2026-06-16 US8062652B2 (en) | 2004-06-17 | 2005-06-17 | Compositions and methods for treating precocious puberty |
US13/291,764 Abandoned US20120114730A1 (en) | 2004-06-17 | 2011-11-08 | Compositions and methods for treating precocious puberty |
US14/456,602 Abandoned US20140349936A1 (en) | 2004-06-17 | 2014-08-11 | Compositions and methods for treating precocious puberty |
US14/935,943 Abandoned US20160193280A1 (en) | 2004-06-17 | 2015-11-09 | Compositions and methods for treating precocious puberty |
US15/407,632 Abandoned US20170119843A1 (en) | 2004-06-17 | 2017-01-17 | Compositions and methods for treating precocious puberty |
US16/002,578 Abandoned US20180280467A1 (en) | 2004-06-17 | 2018-06-07 | Compositions and methods for treating precocious puberty |
US16/793,391 Abandoned US20200179480A1 (en) | 2004-06-17 | 2020-02-18 | Compositions and methods for treating precocious puberty |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/155,822 Active 2026-06-16 US8062652B2 (en) | 2004-06-17 | 2005-06-17 | Compositions and methods for treating precocious puberty |
US13/291,764 Abandoned US20120114730A1 (en) | 2004-06-17 | 2011-11-08 | Compositions and methods for treating precocious puberty |
US14/456,602 Abandoned US20140349936A1 (en) | 2004-06-17 | 2014-08-11 | Compositions and methods for treating precocious puberty |
US14/935,943 Abandoned US20160193280A1 (en) | 2004-06-17 | 2015-11-09 | Compositions and methods for treating precocious puberty |
US15/407,632 Abandoned US20170119843A1 (en) | 2004-06-17 | 2017-01-17 | Compositions and methods for treating precocious puberty |
US16/002,578 Abandoned US20180280467A1 (en) | 2004-06-17 | 2018-06-07 | Compositions and methods for treating precocious puberty |
Country Status (4)
Country | Link |
---|---|
US (7) | US8062652B2 (en) |
EP (1) | EP1773293B1 (en) |
CA (1) | CA2570960C (en) |
WO (1) | WO2006009801A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7759312B2 (en) * | 2005-03-11 | 2010-07-20 | Endo Pharmaceuticals Solutions Inc. | Delivery of dry formulations of octreotide |
US7452868B2 (en) * | 2005-03-11 | 2008-11-18 | Indevus Pharmaceuticals, Inc. | Controlled release formulations of octreotide |
RU2463079C2 (en) * | 2007-04-27 | 2012-10-10 | Эндо Фармасьютикалз Солюшнз Инк. | Separation agents for implanted device and methods for using them |
WO2009158412A2 (en) * | 2008-06-25 | 2009-12-30 | Endo Pharmaceuticals Solutions Inc. | Sustained delivery of exenatide and other polypeptides |
RU2521291C2 (en) * | 2008-06-25 | 2014-06-27 | Эндо Фармасьютикалз Солюшнз Инк. | Octreotide implant containing releasing substance |
US20200330547A1 (en) * | 2019-04-22 | 2020-10-22 | Tolmar International Limited | Method of Treating a Child with Central Precocious Puberty using an Extended Release Composition |
EP4319790A1 (en) * | 2021-04-08 | 2024-02-14 | Enteris BioPharma, Inc. | Methods of treatment of pediatric puberty using oral formulations of leuprolide |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2265226A (en) | 1936-10-17 | 1941-12-09 | Du Pont | Cast resins having integral sheen |
US2513014A (en) | 1946-11-18 | 1950-06-27 | Abbott Lab | Apparatus for implanting medicinal pellets subcutaneously |
GB1306541A (en) | 1969-01-20 | 1973-02-14 | Ceskoslovenska Akademie Ved | Method of manufacturing tubes by centrifugal casting |
US3921632A (en) | 1974-08-16 | 1975-11-25 | Frank M Bardani | Implant device |
US4285987A (en) * | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
US4298002A (en) | 1979-09-10 | 1981-11-03 | National Patent Development Corporation | Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation |
US4959217A (en) * | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
US4871094A (en) | 1986-12-31 | 1989-10-03 | Alcon Laboratories, Inc. | Means and method for dispensing substances |
US4846793A (en) | 1987-03-18 | 1989-07-11 | Endocon, Inc. | Injector for implanting multiple pellet medicaments |
US4994028A (en) | 1987-03-18 | 1991-02-19 | Endocon, Inc. | Injector for inplanting multiple pellet medicaments |
AU608891B2 (en) | 1987-09-24 | 1991-04-18 | Merck & Co., Inc. | Solubility modulated drug delivery device |
US5035891A (en) | 1987-10-05 | 1991-07-30 | Syntex (U.S.A.) Inc. | Controlled release subcutaneous implant |
GB8820353D0 (en) | 1988-08-26 | 1988-09-28 | Staniforth J N | Controlled release tablet |
DE69001831T2 (en) | 1989-02-16 | 1993-09-16 | British Tech Group | ACTIVE SUBSTANCE DELIVERY DEVICE. |
PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
US5273752A (en) * | 1989-07-18 | 1993-12-28 | Alza Corporation | Controlled release dispenser comprising beneficial agent |
US5266325A (en) * | 1990-09-28 | 1993-11-30 | Hydro Med Science Division Of National Patent Development Corp. | Preparation of homogeneous hydrogel copolymers |
AU651654B2 (en) * | 1992-01-14 | 1994-07-28 | Endo Pharmaceuticals Solutions Inc. | Manufacture of water-swellable hydrophilic articles and drug delivery devices |
US5614223A (en) | 1992-05-04 | 1997-03-25 | Digestive Care Inc. | Intraoral medicament-releasing device |
DE69425781T2 (en) * | 1993-06-11 | 2001-01-04 | Nippon Chemi-Con Corp., Ome | Support and connection device for a magnetic field modulation head used in a photomagnetic recording |
US5817343A (en) * | 1996-05-14 | 1998-10-06 | Alkermes, Inc. | Method for fabricating polymer-based controlled-release devices |
DK1007080T3 (en) * | 1996-08-30 | 2007-07-30 | Peptech Ltd | Formulation for sustained release of peptide agonists and analogues of GnRH |
US5945128A (en) * | 1996-09-04 | 1999-08-31 | Romano Deghenghi | Process to manufacture implants containing bioactive peptides |
US5756127A (en) * | 1996-10-29 | 1998-05-26 | Wright Medical Technology, Inc. | Implantable bioresorbable string of calcium sulfate beads |
US5854127A (en) * | 1997-03-13 | 1998-12-29 | Micron Technology, Inc. | Method of forming a contact landing pad |
FI971385A0 (en) | 1997-04-04 | 1997-04-04 | Bioxid Oy | Biocompatible composition, methodological method |
US5854382A (en) | 1997-08-18 | 1998-12-29 | Meadox Medicals, Inc. | Bioresorbable compositions for implantable prostheses |
US20040071736A1 (en) | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
ES2313879T3 (en) | 1999-01-28 | 2009-03-16 | Indevus Pharmaceuticals, Inc. | USEFUL HYDROGEL COMPOSITIONS FOR THE PROLONGED RELEASE OF MACROMOLECULES, AND MANUFACTURING PROCEDURES OF THE SAME. |
US6969480B2 (en) | 2000-05-12 | 2005-11-29 | Matregen Corp. | Method of producing structures using centrifugal forces |
US20030049320A1 (en) | 2000-12-18 | 2003-03-13 | Wockhardt Limited | Novel in-situ forming controlled release microcarrier delivery system |
WO2002078597A2 (en) * | 2001-04-01 | 2002-10-10 | Yeda Research And Development Co. Ltd. Weizmann Institute Of Science | Oral absorbed drugs |
US20040097419A1 (en) | 2002-11-19 | 2004-05-20 | Holger Petersen | Organic compounds |
CA2437639C (en) | 2003-08-11 | 2016-07-05 | Valera Pharmaceuticals, Inc. | Long term drug delivery devices with polyurethane based polymers and their manufacture |
WO2005041873A2 (en) | 2003-10-24 | 2005-05-12 | Azopax Therapeutics Llc | Formulation of exendin-4 |
US20050143303A1 (en) | 2003-12-26 | 2005-06-30 | Nastech Pharmaceutical Company Inc. | Intranasal administration of glucose-regulating peptides |
US7452868B2 (en) | 2005-03-11 | 2008-11-18 | Indevus Pharmaceuticals, Inc. | Controlled release formulations of octreotide |
WO2008061355A1 (en) | 2006-11-24 | 2008-05-29 | Matregen Corp. | Glp-1 depot systems, and methods of manufacture and uses thereof |
-
2005
- 2005-06-17 US US11/155,822 patent/US8062652B2/en active Active
- 2005-06-17 WO PCT/US2005/021368 patent/WO2006009801A2/en active Application Filing
- 2005-06-17 CA CA2570960A patent/CA2570960C/en active Active
- 2005-06-17 EP EP05762243.3A patent/EP1773293B1/en not_active Revoked
-
2011
- 2011-11-08 US US13/291,764 patent/US20120114730A1/en not_active Abandoned
-
2014
- 2014-08-11 US US14/456,602 patent/US20140349936A1/en not_active Abandoned
-
2015
- 2015-11-09 US US14/935,943 patent/US20160193280A1/en not_active Abandoned
-
2017
- 2017-01-17 US US15/407,632 patent/US20170119843A1/en not_active Abandoned
-
2018
- 2018-06-07 US US16/002,578 patent/US20180280467A1/en not_active Abandoned
-
2020
- 2020-02-18 US US16/793,391 patent/US20200179480A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20160193280A1 (en) | 2016-07-07 |
EP1773293B1 (en) | 2015-04-15 |
EP1773293A2 (en) | 2007-04-18 |
US20060019903A1 (en) | 2006-01-26 |
WO2006009801A3 (en) | 2007-01-18 |
US20180280467A1 (en) | 2018-10-04 |
CA2570960A1 (en) | 2006-01-26 |
US8062652B2 (en) | 2011-11-22 |
US20170119843A1 (en) | 2017-05-04 |
US20140349936A1 (en) | 2014-11-27 |
US20120114730A1 (en) | 2012-05-10 |
CA2570960C (en) | 2013-10-01 |
WO2006009801A2 (en) | 2006-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200179480A1 (en) | Compositions and methods for treating precocious puberty | |
US20200353055A1 (en) | Controlled release formulations of octreotide | |
US20190388500A1 (en) | Delivery of dry formulations of octreotide | |
JP2000505419A (en) | Male contraceptive graft | |
Golomb et al. | Intrauterine administration of peptide drugs for systemic effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ENDO PHARMACEUTICALS SOLUTIONS, INC., PENNSYLVANIA Free format text: MERGER AND CHANGE OF NAME;ASSIGNORS:INDEVUS PHARMACEUTICALS, INC.;ENDO PHARMACEUTICALS SOLUTIONS, INC.;REEL/FRAME:052834/0459 Effective date: 20090323 Owner name: INDEVUS PHARMACEUTICALS, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VALERA PHARMACEUTICALS, INC.;REEL/FRAME:052834/0414 Effective date: 20080102 Owner name: VALERA PHARMACEUTICALS, INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KUZMA, PETR;REEL/FRAME:052834/0409 Effective date: 20050701 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
AS | Assignment |
Owner name: WILMINGTON TRUST, NATIONAL ASSOCIATION, DELAWARE Free format text: CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS;ASSIGNORS:BIOSPECIFICS TECHNOLOGIES LLC;PAR PHARMACEUTICAL, INC.;AUXILIUM US HOLDINGS, LLC;AND OTHERS;REEL/FRAME:055845/0618 Effective date: 20210329 Owner name: WILMINGTON TRUST, NATIONAL ASSOCIATION, DELAWARE Free format text: CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS;ASSIGNORS:BIOSPECIFICS TECHNOLOGIES LLC;PAR PHARMACEUTICAL, INC.;AUXILIUM US HOLDINGS, LLC;AND OTHERS;REEL/FRAME:055846/0246 Effective date: 20210329 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: VINTAGE PHARMACEUTICALS, LLC, NEW YORK Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0542 Effective date: 20240423 Owner name: SLATE PHARMACEUTICALS, LLC, PENNSYLVANIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0542 Effective date: 20240423 Owner name: QUARTZ SPECIALTY PHARMACEUTICALS, LLC, NEW YORK Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0542 Effective date: 20240423 Owner name: PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC), NEW YORK Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0542 Effective date: 20240423 Owner name: PAR PHARMACEUTICAL COMPANIES, INC., NEW YORK Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0542 Effective date: 20240423 Owner name: PAR PHARMACEUTICAL, INC., NEW YORK Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0542 Effective date: 20240423 Owner name: GENERICS INTERNATIONAL (US), INC., NEW YORK Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0542 Effective date: 20240423 Owner name: GENERICS BIDCO I, LLC, NEW YORK Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0542 Effective date: 20240423 Owner name: ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.), PENNSYLVANIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0542 Effective date: 20240423 Owner name: ENDO PHARMACEUTICALS INC., PENNSYLVANIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0542 Effective date: 20240423 Owner name: DAVA PHARMACEUTICALS, LLC, NEW YORK Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0542 Effective date: 20240423 Owner name: DAVA INTERNATIONAL, LLC, PENNSYLVANIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0542 Effective date: 20240423 Owner name: BIOSPECIFICS TECHNOLOGIES LLC, PENNSYLVANIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0542 Effective date: 20240423 Owner name: BIOSPECIFICS TECHNOLOGIES CORP., PENNSYLVANIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0542 Effective date: 20240423 Owner name: AUXILIUM US HOLDINGS, LLC, PENNSYLVANIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0542 Effective date: 20240423 Owner name: AUXILIUM PHARMACEUTICALS, LLC, PENNSYLVANIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0542 Effective date: 20240423 Owner name: ASTORA WOMEN'S HEALTH LLC, PENNSYLVANIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0542 Effective date: 20240423 Owner name: ACTIENT PHARMACEUTICALS LLC, PENNSYLVANIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0542 Effective date: 20240423 |
|
AS | Assignment |
Owner name: VINTAGE PHARMACEUTICALS, LLC, NEW YORK Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0795 Effective date: 20240423 Owner name: SLATE PHARMACEUTICALS, LLC, PENNSYLVANIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0795 Effective date: 20240423 Owner name: QUARTZ SPECIALTY PHARMACEUTICALS, LLC, NEW YORK Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0795 Effective date: 20240423 Owner name: PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC), NEW YORK Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0795 Effective date: 20240423 Owner name: PAR PHARMACEUTICAL, INC., NEW YORK Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0795 Effective date: 20240423 Owner name: GENERICS BIDCO I, LLC, NEW YORK Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0795 Effective date: 20240423 Owner name: ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.), PENNSYLVANIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0795 Effective date: 20240423 Owner name: ENDO PHARMACEUTICALS INC., PENNSYLVANIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0795 Effective date: 20240423 Owner name: ENDO GENERIC HOLDINGS, INC. (FORMERLY KNOWN AS PAR PHARMACEUTICALS COMPANIES, INC.), PENNSYLVANIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0795 Effective date: 20240423 Owner name: DAVA PHARMACEUTICALS, LLC, NEW YORK Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0795 Effective date: 20240423 Owner name: DAVA INTERNATIONAL, LLC, PENNSYLVANIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0795 Effective date: 20240423 Owner name: BIOSPECIFICS TECHNOLOGIES LLC, PENNSYLVANIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0795 Effective date: 20240423 Owner name: BIOSPECIFICS TECHNOLOGIES CORP., PENNSYLVANIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0795 Effective date: 20240423 Owner name: AUXILIUM US HOLDINGS, LLC, PENNSYLVANIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0795 Effective date: 20240423 Owner name: AUXILIUM PHARMACEUTICALS, LLC, PENNSYLVANIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0795 Effective date: 20240423 Owner name: ASTORA WOMEN'S HEALTH LLC, PENNSYLVANIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0795 Effective date: 20240423 Owner name: ASTORA WOMEN'S HEALTH HOLDINGS, LLC, MINNESOTA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0795 Effective date: 20240423 Owner name: ACTIENT PHARMACEUTICALS LLC, PENNSYLVANIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0795 Effective date: 20240423 Owner name: GENERICS INTERNATIONAL (US), INC., NEW YORK Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067239/0795 Effective date: 20240423 |
|
AS | Assignment |
Owner name: DISCOVERY ENERGY, LLC, WISCONSIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KOHLER CO.;REEL/FRAME:067289/0516 Effective date: 20240501 |